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 INTRODUCTION 
 
The pharmaceutical and health care industry has been creating and using 
nano-scale materials for resolving many physical, biological and chemical 
problems related with the treatment of disease. The hydrophobic nature of most of 
the drugs presents a challenge for effective in vivo delivery. Shrinking materials to 
nano size has profoundly enhanced the efficacy of such drugs. A number of 
polymers have been studied and used for formulating Novel drug delivery systems 
(NDDS) [1]. 
An ideal drug therapy attains effective drug concentration at the target site 
for a specified period of time and minimizes general and local side effects. To 
obtain a desirable therapeutic response, the correct amount of drug should be 
transported and delivered to the site of action with subsequent control of drug 
input rate. The distribution of drug to other tissues therefore seems unnecessary, 
wasteful and a potential cause of toxicity. Targeted drug delivery is the delivery of 
drug to receptor, organ or any part of the body to which one wishes to deliver the 
drug exclusively. Targeting drug delivery has long been a problem for medical 
researchers i.e., how to get them to the right place in the body and how to control 
the release of the drug to prevent overdoses. The development of new and 
complex molecule called Nanosponges has the potential to solve this problem [2]. 
Nanosponges are made of microscopic particles with few nanometers wide 
cavities, in which a large variety of substances can be encapsulated. These 
particles possess the ability to carry both lipophilic and hydrophilic substances and 
thereby improving the solubility of poorly water soluble molecules. The studies 
conducted in this field proves that the tiny mesh-like structures called nanosponges 
may revolutionise the treatment of many diseases and early trials suggest this 
technology is up to five times more effective at delivering drugs for breast cancer 
than conventional methods [3]. 
The nanosponge is about the size of a virus with a ‘backbone’ (a scaffold 
structure) of naturally degradable polyester. They ‘cross link’ segments of the 
polyester to form a spherical shape that has many pockets (or cavities) where 
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drugs can be encapsulated. The polyester is biodegradable, which means that when 
it breaks down in the body, the drug can be released on a known schedule. 
 
 
           Figure 1: Cyclodextrin based nanosponges 
The nanosponges are encapsulating type of nanoparticles which 
encapsulates the drug molecules within its core. Based on the method of 
associating with drugs, the nanoparticles are classified into encapsulating 
nanoparticles, conjugating nanoparticles and complexing nanoparticles. The 
encapsulating nanoparticle is represented by nanosponges and nanocapsules. 
Nanosponges such as alginate nanosponge, which are sponge like nanoparticles 
contains many holes that carry the drug molecules. The second category is 
conjugating nanoparticle, which links to drugs through covalent bonds. The third 
type is complexing nanoparticle, which attracts the molecules by electrostatic 
charges [4]. 
The nanosponges are solid in nature and can be formulated as oral, 
parenteral, topical or inhalational dosage forms. For oral administration, these may 
be dispersed in a matrix of excipients, diluents, lubricants and anticaking agents 
which is suitable for the preparation of tablets or capsules. For parenteral 
administration, these can be simply mixed with sterile water, saline or other 
aqueous solutions. For topical administration, they can be effectively incorporated 
into topical hydrogel [5]. 
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 When compared to the other nanoparticles, they are insoluble both in 
water and organic solvents, porous, non-toxic and stable at high temperatures up to 
300°C. They are capable of capturing, transporting and selectively releasing a 
huge variety of substances because of their specific 3D structure containing 
cavities of nanometric size and tunable polarity. Furthermore, nanosponges show a 
notable advantage in comparison with the common nanoparticles that is, they can 
be easily regenerated by different treatments, such as washing with eco-compatible 
solvents, mild heating, stripping with moderately inert hot gases or changing ionic 
strength or pH [6]. 
 The simple chemistry of polymers and cross linkers poses no problems in 
the preparation and this technology can be easily ramped up to commercial 
production levels. They can be mixed with water and used as a transport fluid. 
They are also used to mask unpleasant flavours, to convert liquid substances to 
solids. The chemical linkers allow the nanosponges to bind preferentially to the 
target site [7]. 
The nanosponges could be either in crystalline or in paracrystalline form. 
The loading capacity of nanosponges depends mainly on the degree of 
crystallisation. Paracrystalline nanosponges show different loading capacities. The 
nanosponges can be formulated to be of specific size and to release drugs over 
time by varying the proportion of cross linker to polymer. These nanosponges can 
be magnetized when they are synthesised in the presence of compounds having 
magnetic properties. The tiny shape of nanosponges enables the pulmonary and 
venous delivery of drug in a controlled manner [8]. 
Targeting Sites by Nanosponges 
 “Tagging” drug-loaded nanosponges ensures desired pharmacological 
response by targeting only disease affected cells and leaving the healthy ones 
unharmed. Drugs encapsulated within the nanosponge pores are shielded from 
premature destruction and stability of drug is enhanced. This tiny sponge 
circulates around the tumour cell until they encounter the surface to release their 
drug cargo in a sustained manner [9]. Nanosponge is three to five times more 
effective at decreasing tumour growth than direct injection. The targeted delivery 
systems of nanosponge have several basic advantages like, the drug is released at 
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the tumour instead of circulating widely through the body, and it is more effective 
for a given dosage. The nanosponges have basic features such as fewer harmful 
side effects as smaller amounts of the drug will come into contact with healthy 
tissue [5]. 
Difference between Nanoparticles and Nanosponges 
The thin line of distinction among nanoparticles and nanosponges is the 
difference in porosity and size. Nanoparticles have size in nanometer whereas 
nanosponges have pores in nanometers while their overall size can extend up to 
micrometers, and are usually smaller than 5μm. Many times nanosponges have 
been reported as nanoporous nanoparticles / microparticles. Nanosponges show 
diverse domains in their structure, since they have both hydrophobic and 
hydrophilic groups. 
  
 
Figure 2: Polymer based nanosponges 
 
ADVANTAGES OF NANOSPONGES  
1) Being amphiphilic in nature, nanosponges can carry both hydrophobic molecules 
in the hydrophobic cavity and hydrophilic molecules in the spaces between the 
hydrophobic moieties simultaneously. Hydrophobic drugs can be loaded into the 
nanosponge structure to consequently increase their solubility. 
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2) The superior properties of nanosponges have been attributed to ‘tunability’, that is 
the ability to control the structure of particles and control the nature and size of 
aperture. 
3)  Nanosponges have the ability to produce predictable/controlled drug release [1]. 
4) Nanosponges can be tagged with specific linkers to target diseased cells hence 
achieving greater efficacy while reducing side-effects, decreasing dose and dosing 
frequency and in turn increasing patient compliance. 
5) Nanosponges can significantly reduce the irritation of drugs without reducing their 
efficacy. 
6)  Biodegradable in nature and easy scale up for commercial production [10]. 
7) They mix with water and are used as a transport fluid. They can be used to mask 
unpleasant flavours [11]. 
 
DISADVANTAGE 
The only disadvantage of this nanosponges is their ability to include only 
small molecules. 
 
 CHARACTERISTIC FEATURES OF NANOSPONGES [12] 
 Nanosponges of specific size can be synthesized by changing the 
crosslinker to polymer ratio. 
 They are nontoxic, porous particles, insoluble in most organic solvents and 
stable up to 300⁰C. They are stable at the pH range of 1-11. 
 They form clear and opalescent suspension in water. 
 They can be reproduced by simple thermal desorption, extraction with 
solvents, by using microwaves and ultrasounds. 
 Their three-dimensional structure allows capture, transportation and 
selective release of a variety of substances. 
 Chemical linkers permit nanosponges to bind preferably to the target site. 
 By complexing with different drugs nanosponges can form inclusion and 
non-inclusion complexes. 
 By adding magnetic particles into the reaction mixture, magnetic 
properties can also be imparted to nanosponges. 
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POLYMERS USED IN NANOSPONGES PREPARATION [5]  
There are various polymers and cross linkers are used in the preparation of 
nanosponges.  
Polymers: Hyper cross linked Polystyrenes, Cyclodextrines and its derivatives 
like Alkyloxycarbonyl Cyclodextrins, Methyl β-Cyclodextrin, Hydroxy Propyl β-
Cyclodextrins.  
Copolymers: Poly(valerolactoneallylvalerolactone), Poly(valerolactoneallylvalero 
-lactone oxepanedione), Ethyl Cellulose, Poly vinyl alcohol. 
Cross linker: Carbonyl diimidazoles, Carboxylic acid dianhydrides, 
Diarylcarbonates, Dichloromethane, Diisocyanates, Diphenyl Carbonate, 
Epichloridine, Gluteraldehyde, Pyromellitic anhydride, 2,2-bis (acrylamido)Acetic 
acid. 
 
PREPARATION OF NANOSPONGES 
Nanosponges are prepared mainly on the criteria of delivery system, 
polymer and nature of drug and solvents. 
1) Nanosponges prepared from hyper-cross linked β-cyclodextrins: 
β-cyclodextrin nanosponges were prepared by placing 100ml of dimethyl 
formamide (DMF)  in a round bottomed flask and 17.42g of anhydrous β-CD was 
added and shaken to achieve complete dissolution. Then 9.96g of carbonyl di-
imidazole (61.42m mol) was added and the solution was allowed to react for 4hrs 
at 1000°C. Once condensation polymerization was complete, the block of hyper 
cross linked cyclodextrin was roughly ground and an excess of deionised water 
was added to remove DMF. Finally residual by-products or unreacted reagents 
were completely removed by soxhlet extraction with ethanol [8]. 
The white powder thus obtained was dried overnight in an oven at 600°C. The 
fine powder obtained was dispersed in water. The colloidal part that remained 
suspended in water was recovered and lyophilized. The obtained nanosponges are 
sub-micron in dimension and with a spherical shape [7]. 
2) Emulsion solvent diffusion method: 
Nanosponges can be prepared by using different proportion of ethyl cellulose 
and polyvinyl alcohol. The dispersed phase containing ethyl cellulose and drug 
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was dissolved in 20ml dichloromethane and slowly added to a definite amount of 
polyvinyl alcohol in 150ml of aqueous continuous phase. The reaction mixture 
was stirred at 1000 rpm for 2hrs in a magnetic stirrer. The nanosponges formed 
were collected by filtration and dried in oven at 40°C for 24hrs. The dried 
nanosponges were stored in vaccum desiccators to ensure the removal of residual 
solvents [2]. 
 
 
Figure 3: Preparation of nanosponges by emulsion solvent diffusion method 
 
3) Quasi-emulsion solvent diffusion: 
  The inner phase is prepared using eudragit RS 100 and added to a suitable 
solvent. Drug to be incorporated is made into a solution and dissolved under 
ultrasonication at 35ºC. This inner phase added into external phase containing 
polyvinyl alcohol which acts as emulsifying agent. The mixture is then stirred at 
1000-2000 rpm for 3hr at room temperature and dried in an hot air oven at 40ºC 
for 12hr [7]. 
4) Ultrasound- Assisted Synthesis:  
In this method, polymers react with cross- linkers in absence of solvent and 
under sonication. Here, the polymer and cross- linker are mixed in a flask. Place 
the flasks in an ultrasound bath filled with water and heated to 90°C and then 
sonicate for 5 hrs. It was then allowed to cool and washed with water to remove 
the unreacted polymer. Dry the product under vacuum and store at 250°C [8]. 
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LOADING OF DRUG INTO NANOSPONGES   
 Suspend the prepared nanosponges in water and sonicate to avoid the 
presence of aggregates and then centrifuge the suspension to collect the colloidal 
fraction. Separate the supernatant and then dry the sample by freeze drying. The 
aqueous suspension of nanosponges was prepared and dispersed the amount of the 
drug to be loaded in it. Maintain the suspension under constant stirring for specific 
time required for complexation. After complexation, separate the uncomplexed 
(undissolved) drug from complexed drug by centrifugation. Then obtain the solid 
crystals of nanosponges by solvent evaporation or by freeze drying [7].  
FACTORS AFFECTING DRUG RELEASE FROM NANOSPONGES 
1. Physical and chemical properties of entrapped active pharmaceutical     
ingredients.  
2. Physical properties of sponge system such as pore diameter, pore volume, and 
resiliency.  
3.  Properties of vehicle, in which the sponges are finally dispersed.  
4. Particle size, pore characteristics, and compositions can be considered as vital 
parameters  
5.  External triggers such as pressure, temperature, and solubility of actives  
6. Temperature: Some entrapped actives can be too viscous at room temperature to 
flow spontaneously from sponges onto the skin but increased skin or 
environment temperature can result in increased flow rate and ultimately drug 
release [13]. 
 
CHARACTERIZATION OF NANOSPONGES  
1. Particle size determination  
The sizes of particles are maintained during polymerization for the 
formation of free-following powders having fine aesthetic appearance. Particle 
size analysis of loaded and unloaded nanosponges can be carried out by laser light 
diffractometry or Malvern zeta sizer [14]. 
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2. Determination of loading efficiency  
 The loading efficiency of prepared nanosponge is determined by 
subtracting the un-entrapped drug from the total amount of drug. The un-entrapped 
drug must be estimated by any suitable method of analysis. The method used for 
separation of un-entrapped drug by gel filtration, dialysis and ultra centrifugation. 
The loading efficiency is calculated as:  
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑛𝑎𝑛𝑜𝑠𝑝𝑜𝑛𝑔𝑒
 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 
  ×  100 
3. Compatibility Studies  
The drug should be compatible with the polymers which are used for the 
preparation of nanosponges. The compatibility of drug with adjuvants can be 
determined by Thin Layer Chromatography (TLC) and Fourier Transform Infra-
red Spectroscopy (FT-IR). Crystalline characteristics can be studied by powder X-
ray diffraction (XRD) and Differential Scanning Colorimetry (DSC) [13] 
4. Zeta Potential  
Zeta potential is a measure of surface charge. The surface charge of 
nanosponge can be determined by using Zeta sizer [15]. 
5. Solubility studies  
The most widely used approach to study inclusion complexation is the 
phase solubility method described by Higuchi and Connors, which examines the 
effect of a nanosponge, on the solubility of drug. Phase solubility diagrams 
indicate the degree of complexation [16]. 
6. Drug release kinetics  
To investigate the mechanism of drug release from the nanosponge the 
release data was analysed using Zero order, First order, Higuchi, Korsemeyer-
Peppas models. The data can be analysed using DD solver software. The software 
estimates the parameters of a non-linear function that provides the closest fit 
between experimental observations and non- linear function [17]. 
7. In vitro release studies   
In vitro release kinetics experiments are carried out using a multi 
compartment rotating cell. An aqueous dispersion of nanosponges (1ml) 
containing the drug is placed in the donor compartment, while the receptor 
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compartment separated by a hydrophilic dialysis membrane is filled with 
phosphate buffer of requires pH. The experiment is carried out for 24hr. At fixed 
time intervals, the receptor buffer is completely withdrawn and replaced with fresh 
buffer. The amount of drug in the medium is determined by the suitable analytical 
method and drug release is calculated to determine the release pattern [11].  
8. Microscopy studies  
Scanning Electron Microscopy (SEM) and Transmission Electron 
Microscopy (TEM) can be used to study the microscopic aspects of the 
nanosponges. The difference in crystallization state of the raw materials and the 
product seen under electron microscope indicates the formation of the inclusion 
complexes [8]. 
 
MARKETED FORMULATIONS 
Table 1: Marketed formulations of nanosponges 
Drug  Administration Route  Trade Name  Dosage Form  
Dexamethasone  Dermal  Glymesason  Tablet  
Iodine  Topical  Mena- gargle  Solution  
Alprostadil  I.V  Prostavastin  Injection  
Piroxicam  Oral  Brexin  Capsule  
 
APPLICATIONS 
Nanosponges have many applications in the pharmaceutical field due to their 
biocompatibility and versatility. Some of them are as follows. 
a) Nanosponges in Solubility Enhancement: 
Presence of crosslinking agent and cavities in the nanosponge structure 
helps interaction with active molecules. These features allow several substances to 
be included and get solubilized in the thus formed cavities. The hydrophilic 
hydroxyl groups on the external surface remain exposed to the environment, while 
the hydrophobic functionality of the complex hides in the interior cavity of the 
cyclodextrin the net effect is that a water soluble complex is formed [18]. 
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b) Nanosponges in Drug Delivery: 
Nanosponges have spherical shape and nanometric in size making them 
ideal in preparing various dosage forms like topical, parenteral, aerosol, tablets 
and capsules. It is found that highest solubility and in vitro drug release is 
observed in inclusion complex [19].  
c) Nanosponges for Protein Delivery: 
The major obstacle in protein formulation development is the maintenance 
of the native protein structure both during the formulation process and upon the 
long term storage. The nanosponges were found to be stable at 300°C and high 
protein complexation capacity was also observed. 
d) Nanosponges in Enzyme Immobilization: 
The enzyme immobilization is particularly relevant for lipases, as it 
improves their stability and modifies properties like enantioselectivity as well as 
the reaction rates. As a consequence, the demand for new solid supports, suitable 
for family of enzymes is constantly growing [3]. 
e) Nanosponges as a Carrier for Delivery of Gases: 
  Hypoxia (deficiency of adequate oxygen supply) is related to various 
pathologies, from inflammation to cancer. Sometimes it can be difficult to deliver 
oxygen in appropriate form and doses in clinical practice. Nanosponge 
formulations were developed as oxygen delivery systems for topical application 
which were having the ability to store and to release oxygen slowly over time [20]. 
f) Nanosponges as Protective Agent -against Photo Degradation: 
Nanosponges were prepared by encapsulating gamma-oryzanol showing a 
good protection from photodegradation. Gamma-oryzanol (a ferulic acid ester 
mixture), an anti-oxidant and usually employed to stabilize food and 
pharmaceutical raw materials, moreover, used as a sunscreen in the cosmetics 
industry. Its applications are limited due to its high instability and 
photodegradation. With the gammaoryzanol loaded nanosponges a gel and an O/W 
emulsion are formulated [7]. 
g) Modulating Drug Release: 
A drug loaded into the nanosponge is retained and released slowly over 
time. Hydrophilic nanosponges are employed to enhance the drug absorption 
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across biological barriers, to modify the drug release rate and as a potent drug 
carrier in immediate release formulations. Hydrophobic nanosponges are utilized 
as sustained release carriers for water soluble drugs, including peptide and protein 
drugs and they protect the drug during its passage through the stomach. This drug 
is released very slowly at pH 1.1, whereas release is faster if pH is raised to 7.4. 
h) Effective Delivery Carriers: 
Antitumor drugs such as paclitaxel, camptothecin and tamoxifen shows 
bioavailability problem (because of poor aqueous solubility) hence nanosponges 
can be used as vehicles in order to improve their solubility as well as 
bioavailability. Complexes showed high effect than that of the drug alone. After 
loading the drug in nanosponges the mean absolute bioavailability of paclitaxel 
was increased and found to be 2.5 fold higher than the plain drug [21]. 
Future Prospects 
Nanosponges are effective carriers for targeted delivery of drugs to lungs, 
liver and spleen. A simple approach for formulating Palladium/Silver and 
Palladium/Silver/Aluminium nanosponges, which contain network of nanowires 
has been reported. This strategy establishes the first time preparation of alloy 
nanosponges with network nanowires via self-regulated reduction of sodium 
dodecylsulfate (SDS) and adding the second or third metal salt during synthesis 
without additional reducing agent. Further studies on kinetics and biochemical 
interactions of nanosponges within organisms are vital. These studies must mainly 
focus on research on nanosponges translocation pathways, its accumulation in the 
targeted area, short and long-term toxicity, their interactions with cells, the 
receptors and signalling pathways involved, cytotoxicity, and their surface 
functionalization for an effective phagocytosis [22]. There is only a sparse 
knowledge about the effects of nanosponges exposure on the lymphatic and 
immune systems, as well as various organs. In order to clarify the possible role of 
nanosponges in diseases recently associated with them (such as Crohn’s disease, 
neurodegenerative diseases, autoimmune diseases, and cancer), nanoscale 
characterization techniques should be used to a larger extent to identify 
nanosponges at disease sites in affected organs or tissues, and to establish relevant 
interaction mechanisms. The cytotoxicity of the nanoparticles or their degradation 
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product remains a major problem and also the improvement in the 
biocompatibility obviously is a serious concern for the future [7]. 
 
SILYMARIN 
Silymarin, a potential phytochemical compound obtained from the seeds of 
Silybum marianum (milk thistle) plant has been used as a hepatoprotective agent 
for more than a decade. Silymarin shows strong anti-oxidant effect through 
scavenging free radicals and inhibiting peroxidation of lipids. The drug is well 
tolerated and has relatively few adverse effects. The effectiveness of silymarin as 
hepatoprotective agent was diminished by its poor water solubility and low 
bioavailability. The poor bioavailability is mainly due to extensive metabolism, 
poor aqueous solubility and rapid excretion through urine and bile, and low 
permeability across intestinal epithelial cells. Besides silymarin has been 
extensively studied in vitro and in vivo for its cancer chemopreventive potential 
against various cancers. 
The oral bioavailability of silibinin, however, is extremely low (b1%) 
caused primarily by its poor gut absorption and phase II metabolism in the liver. It 
was determined that gut permeability was not the rate-limiting step in the gut 
absorption of silibinin; instead it was the slow dissolution rate of silibinin due to 
its poor solubility in the gastrointestinal fluid. The high incidence of 
administration of silymarin together with its short half-life and poor bioavailability 
proposed great scope for the proposal and development of nanoparticulate drug 
delivery systems [23]. 
Silymarin as Anticancer Agents 
Several studies have demonstrated Silymarin’s anticancer effects by 
causing cell arrest and inducing apoptosis in different types of cancers. Silymarin 
induces apoptotic cell death in CH11-treated human malignant melanoma A375-
S2 cells through an increased expression of Fas-associated proteins with death 
domain (FADD), which is a downstream molecule of the death receptor pathway, 
subsequent to the cleavage of procaspase-8 that induces apoptosis [24]. 
 Breast cancer is the leading cause of cancer-related deaths among women 
in the world, and the metastasis of the cancerous cells is responsible for over 90% 
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of the deaths of these cancer patients. The nano sized drug delivery system 
(NDDS) is a promising strategy for increasing the accumulation of drugs in the 
tumour because of its enhanced penetration and retention (EPR) effects and for 
minimizing side effects [25]. 
Although the exact mechanisms involved in antineoplastic effects of 
silymarin in breast cancer have not been identified, possible underlying 
explanations include induction of G1 arrest and apoptosis through inhibiting 
cyclin- dependent kinases activity and epidermal growth factor receptor signalling, 
and increasing Cip1/p21 and p27.Breast cancer is a major health problem more 
commonly seen in the developed countries [26]. 
Silymarin Nanoformulations 
Although considerable recent approaches have been made through 
nanotechnology by employing self-nano emulsifying drug delivery system, PLGA, 
chitosan, stearic acid modified polysaccharide and polymeric nanoparticles, the 
bioavailability problems of silymarin have not been solved to date [23]. 
Hence, not coincidentally, a majority of studies on bioavailability 
enhancement of silibinin set their aims at improving the dissolution rate by means 
of nanonization to take advantage of the large specific surface areas afforded by 
nanoparticles. Various nanoformulation platforms ranging from liposomes, solid 
lipid nanoparticles, and polymer nanoparticles to porous silica nanoparticles and 
nano-emulsions have been employed as delivery vehicles for silibinin. These 
nanoformulation strategies, however, possess a major drawback in their low 
silibinin payloads. The low payload leads to a high dosing requirement to achieve 
the therapeutic effect in which a large fraction of the administered dose is made up 
of carrier materials that not only end up wasted, but also possibly have adverse 
health effects due to their large amount. Moreover, the high dosing requirement 
would make therapy regimen of silibinin too costly for most patients, hence 
limiting its potential for widespread clinical applications [27]. 
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OPTIMIZATION: 
Optimization is the process of finding out the best way of using existing resources 
while taking into account of the factors that influences decision in any experiment. 
Advantages of optimization: 
 Reduce the cost 
 Save the time 
 Reduce chances of error 
 Reproducibility, innovation and efficiency 
 
The objectives of the present work were to improve the solubility and thereby the 
bioavailability of silymarin by formulating it into nanosponges. Subsequently the 
prepared silymarin nanosponges were investigated for their particle size, stability, 
preparation efficiency (silymarin utilisation, overall yield) and drug release. 
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RATIONALE FOR THE STUDY 
Criteria for Drug Selection: 
 Molecular weight of drug must be between 100-400D. 
 Structure should contain no more than 5 condensed rings. 
 Solubility of drug must be less than 10mg/mL. 
 Melting point must be less than 250°C. 
 
WHY SILYMARIN ? 
 Silymarin even though has no lipophilic structure in its molecule has low 
aqueous solubility.  
 Under BCS, silymarin is classified as class II drug i.e poorly soluble and 
highly permeable drug. 
 Silymarin was found to possess poor absorption, rapid metabolism and 
ultimately poor oral bioavailability. 
  Only 20-50 % of silymarin is being absorbed after oral administration 
from the GIT after which it undergoes entero-hepatic circulation.[28] 
 So the drug release patterns of silymarin have to be augmented by means 
of various solubility enhancement techniques like nanonization. 
 Number of studies has established the cancer chemopreventive role of 
silymarin in both in vivo and in vitro models. 
 Several studies have demonstrated silymarin’s anticancer effects by 
causing cell cycle arrest and inducing apoptosis in different type of cancers 
like breast cancer, lung cancer, colorectal cancer, oesophageal cancer 
prostate cancer etc. [29]. 
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LITERATURE RIVIEW 
 
 Priyanka et al. (2018) formulated ibuprofen loaded nanosponges for 
topical application. Emulsion solvent diffusion method was selected to prepare 
ibuprofen loaded nanosponges using different ratios of drug: polymer. The 
obtained nanosponges have been evaluated for physicochemical characteristics 
and in vitro release studies. The shape and morphology of drug loaded 
nanosponges were investigated and confirmed by SEM. FTIR results were in 
agreement with standard spectral studies and moreover it was identified that there 
was no interaction between drug and polymer. Entrapment efficiency of the NS 
was found to be around 70.41%. The production yield and in vitro release studies 
was also good. Overall this study resulted in porous nature of nanosponges which 
provides a channel for the release of the drug and the method is quick and 
reproducible [30]. 
 Sornsuvit et al. (2018) aimed to determine the pharmacokinetic 
parameters and bioavailability of silymarin 140mg self micro-emulsifying drug 
delivery system (SMEDDS) formulation. An open-label, single-dose 
pharmacokinetic study was conducted. Twelve healthy volunteers were included 
in the study. After the volunteers had fasted overnight for 10 h, a single-dose 
generic silymarin 140mg SMEDDS soft capsule was administered. Then 10ml 
blood samples were taken at 0.0, 0.25, 0.50, 0.75, 1.0, 1.33, 1.67, 2.0, 2.5, 3.0, 4.0, 
6.0, 8.0, 10.0, and 12.0 h. The plasma silymarin concentrations were analysed 
using validated LC-MS/MS. The pharmacokinetic parameters were analysed and 
calculated. The pharmacokinetic parameters were calculated after silymarin had 
been administered as a single capsule. The mean (range) Cmax was 812.43 
(259.47–1505.47) ng/ml at 0.80 (0.25–1.67) h (tmax). The mean Ke and t1/2 were 
0.5386 h-1 and 1.91 h respectively. The silymarin SMEDDS formulation soft 
capsule showed rapid absorption and high oral bioavailability [31]. 
 Gangadharappa et al. (2017) proposed the study to improve the solubility 
of Celecoxib using β-cyclodextrin and NN-methylene bisacrylamide nanosponge 
hydrogel formulation. Celecoxib is an extremely lipophilic and poorly water 
soluble NSAID which has gastrointestinal side effects when used chronically. 
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Solubility of celcoxib is 7.6μg/ml and therefore the oral bioavailability of 
celecoxib is 40% when administered as a capsule dosage form. Nanosponges of 
celecoxib were prepared and characterized by differential scanning colorimetry, 
X-ray diffractometry, FT-IR analysis and evaluated by Zeta-potential and 
Polydispersity index and drug entrapment efficiency. Further, celecoxib 
nanosponges were dispersed in 1% carbopol 934 hydrogel and the gel was 
evaluated for its viscosity, pH, spreadability, in vitro diffusion. In vivo, 
pharmacokinetic and skin irritation studies conducted using rats. Solubility of 
freeze dried nanosponge particles were in the range of 230 - 490 μg/ml, which 
indicates 30 to 65 fold increases in the solubility compared to pure drug. These 
results confirm that nanosponge formulation is ideal for increasing the solubility 
and bioavailability of poorly water soluble drug like celecoxib [32]. 
 Shilpa et al. (2017) developed and characterized silybin loaded solid lipid 
nanoparticle gel for irritant contact dermatitis (ICD). sICD is associated with 
reduced skin water content, emerging in dry skin condition and relapsing eczema. 
In this study, the silybin loaded nanoparticles was prepared by the ultrasonic 
probe sonication method and further evaluated for particle size and entrapment 
efficiency. Results of optimized batch showed mean particle size 139±0.35 nm 
and entrapment efficiency 90.97±0.91%. Optimized batch was freeze dried and 
characterized by field emission scanning electron microscopy (FE-SEM), it shows 
particles are in nano range, with spherical morphology and smooth surface. 
Finally, the nanoparticles were incorporated into gel for convenient topical 
application. The gel were evaluated for in vitro skin occlusivity, skin irritation and 
ex vivo diffusion and deposition study and further compared with plain gel. 
Efficacy of gel on dinitrochlorobenzene (DNCB) induced ICD mice were 
evaluated by skin water content, ear swelling and histopathology. Ex vivo study of 
gel exhibited prolonged drug release, whereas the skin irritation study shows no 
irritancy [33]. 
 Cristian Radu  et al. (2017) aimed to address one of the major challenges 
of the actual era of nanomedicine namely, the bioavailability of poorly water 
soluble drugs such as Silymarin by developing new, biodegradable, and 
biocompatible nanosized shuttles for Silymarin targeted delivery in colon-cancer 
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cells. The design of these 100 nm sized carrier nanoparticles was based on natural 
polymers and their biological properties such as cellular uptake potential, 
cytotoxicity and 3D penetrability were tested using a colon cancer cell line (HT-
29) as the in vitro culture model. Comparative scanning electron microscopy 
(SEM) and atomic force microscopy (AFM) measurements demonstrated that the 
Silymarin loaded Poly(3-HydroxyButyrate-co-3-HydroxyValerate) (PHBHV) 
nano carriers significantly decreased HT-29 cells viability after 6 and 24 h of 
treatment. Moreover, in vivo like toxicity studies on multicellular tumour 
spheroids showed that the Silymarin loaded PHBHV nano carriers are able to 
penetrate 3D micro tumours and significantly reduce their size [34]. 
 El-Nahas et al. (2017) formulated and characterized silymarin-loaded 
Eudragit nanoparticles (SNPs) and evaluated their hepatoprotective and cytotoxic 
effects after oral administration. SNPs were prepared by nanoprecipitation 
technique and were evaluated for particle size, entrapment efficiency, TEM, solid-
state characterization, and in vitro drug release. The hepatoprotective activity was 
evaluated after oral administration of selected SNPs in carbon tetrachloride-
intoxicated rats. Potential in vivo acute cytotoxicity study was also assessed. 
Morphology of the selected SNPs revealed spherical and uniformly distributed 
nanoparticles. DSC and FT-IR studies suggested the presence of silymarin in an 
amorphous state and absence of chemical interaction. The hepatoprotective 
evaluation of the selected SNPs in CCl4 intoxicated rats revealed significant 
improvement in the activities of different biochemical parameters compared to the 
marketed product. The histopathological and toxicity studies were also carried out. 
The obtained results suggested that the selected SNPs were safe and potentially 
offered enhancement in the pharmacological hepatoprotective properties of 
silymarin [35]. 
 Ahmad et al. (2017) developed and optimized nanoemulsion of silymarin. 
Nanoemulsion was made by aqueous titration method. Sefsol 218, Kolliphor 
RH40 and polyethylene glycol 400 were used as oil phase, surfactant and co-
surfactant while distilled water acted as an aqueous phase. Nanoemulsion was 
characterized on the basis of particle size, viscosity, electrical conductivity and 
refractive index. Further, in vitro release, in vivo pharmacokinetic study, stability 
Literature Review 
 
Department of Pharmaceutics  20 
 
study and cancer cell line studies were also performed. The stability study also 
showed considerably stable formulations at refrigerator temperature as compared 
with room temperature. The cancer cell line studies also confirmed that silymarin 
nanoemulsion reduced the cell viability. The results concluded that nanoemulsion 
may be an efficient carrier for oral delivery of silymarin against human 
hepatocellular carcinoma without damaging normal cells [36]. 
 Hsuan et al. (2017) assembled flavonoid silymarin and zein into spherical 
silymarin-zein nanoparticles that could be effectively adsorbed onto bacterial 
cellulose nanofibers. Silymarin-zein nanoparticles greatly changed the wettability 
and swelling property of bacterial cellulose films due to the formation of 
nanoparticles/nanofibers nanocomposites. Silymarin-zein nanoparticles enhanced 
the release of sparingly soluble silymarin from the nanocomposite films. The 
active films showed more effective antioxidant and antibacterial activities as 
compared with pure films and thus were able to protect salmon muscle from 
deterioration and lipid oxidation. These findings suggest that the 
nanoparticle/nanofiber composites may offer a suitable platform for modification 
of bacterial cellulose films with improved drug release properties and biological 
activities [37]. 
 Younis et al. (2016) developed nano-formulations of silymarin (SM), a 
drug commonly used for liver diseases, to overcome its poor solubility and poor 
bioavailability; antifibrotic effect of these formulations has not been tested yet. 
This study was aimed to formulate and evaluate silymarin-loaded eudragit RS100 
nanoparticles (SMnps) and to test the capability of SMnps to reverse an 
established fibrosis model. SMnps were prepared by solvent evaporation and 
nano-precipitation techniques. The influence of drug: polymer ratio, concentration 
of surfactant in the aqueous phase on particle size, drug entrapment efficiency 
(EE) % and in vitro drug releases were investigated. Formulations of SMnps 
represent a step forward in the field of anti-fibrotic drug development [38]. 
 Bhagyashree Subhash P. and Dr. Mohite S. K (2016) aimed to produce 
controlled release artesunate nanosponges for topical and oral delivery. 
Nanosponges using three different polymers ethyl cellulose, Poly (methyl 
methacrylate) and Pluronic F-68 (poloxamer 188) were prepared successfully 
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using PVA as surfactant by emulsion solvent evaporation method. The effects of 
different drug: polymer ratios, surfactant concentration, stirring speeds and time, 
sonication time on the physical characteristics of the nanosponges as well as the 
drug entrapment efficiency of the nanosponges were investigated. Particle size 
analysis and surface morphology of nanosponges were performed. The scanning 
electron microscopy of nanosponges showed that they were spherical in shape and 
spongy in nature. These small sponges can circulate around the body until they 
encounter the target site and stick on the surface and began to release the drug in a 
controlled and predictable manner which is more effective for a particular given 
dosage [39]. 
 Amiri et al. (2016) prepared nanoniosomal silibinin and evaluate its 
cytotoxicity in the T-47D breast cancer cell line. Silibinin is a chemotherapeutic 
agent active against cancer. Niosomes are biodegradable, biocompatible, safe and 
effective carriers for drug delivery. Niosomes were prepared by reverse phase 
evaporation of a mixture of span 20, silibinin, PEG-2000 and cholesterol in 
chloroform and methanol solvent (1:2 v/v). The solvent phase was evaporated 
using a rotary evaporator and the remaining gel phase was hydrated in phosphate 
buffer saline. Mean size, size distribution and zeta potential of niosomes were 
measured with a Zetasizer instrument and then nanoparticles underwent scanning 
electron microscopy. The drug releasing pattern was evaluated by dialysis and the 
cytotoxicity of nanoniosomes in T-47D cells was assessed by MTT assay. The 
amount of encapsulated drug and the level of drug loading were determined 98.6 ± 
2.7% and 22.3 ±1.8%, respectively; released drug was estimated about 18.6±2.5% 
after 37 hours. The cytotoxic effects of nanoniosome were significantly increased 
when compared with the free drug. This study finding suggests that silibinin 
nanoniosomes could serve as new drug formulation for breast cancer therapy [40]. 
 Zhang et al. (2016) carried out a study with the objective to prepare 
silyblin nanoparticles (NPs) and optimize the prepared nanoparticles using central 
composite rotatable design-response surface methodology. Hepatocellular 
carcinoma (HCC) is a most common liver malignancy. HCC was induced in rats 
by supplementing 100 mg/L of diethylnitrosamine (DENA) in drinking water for 
8 weeks. Saline, silybin 30 mg/kg body weight and nanoformulation of silybin 
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equivalent to silybin dose were administered orally to 3 groups of 6 animals each. 
Anticancer activity was evaluated by counting the liver nodules. The results 
showed that silybin NPs under optimized conditions gave rise to the entrapment 
efficiency (EE) of 88%, drug loading of 15%, mean diameter of 216 nm of the 
NPs prepared and zeta potential value of -15 mV. In rats treated with silybin NPs, 
the number of neoplastic nodules was significantly lower, the animals did not 
exhibit decrease in mean body weight, the number of liver nodules was reduced 
by >93% with significantly high localization in the liver.  It was concluded that 
orally administered silybin NPs showed improved efficacy and safety compared to 
silybin for the treatment of HCC in rats [41]. 
 Li J. et al. (2016) determined the expression status and role of AMPK in 
esophageal squamous cell carcinoma (ESCC) and investigated whether silibinin, a 
nontoxic natural product, could activate AMPK to inhibit ESCC development. 
Emerging evidence suggested that activation of adenosine monophosphate-
activated protein kinase (AMPK) may suppress cancer growth. We found that 
silibinin induced apoptosis, and inhibited ESCC cell proliferation in vitro and 
tumorigenicity in vivo without any adverse effects. Silibinin also markedly 
suppressed the invasive potential of ESCC cells in vitro and their ability to form 
lung metastasis in nude miceThis preclinical study supported that AMPK is a 
valid therapeutic target and suggested that silibinin may be a potentially used as a 
therapeutic agent and chemo sensitizer for oesophageal cancer [42]. 
 Viswanad V. and Jilsha G.  (2015) formulated cephalexin into 
nanosponge loaded hydrogel as it can enhance skin permeation. Nanosponges of 
cephalexin were prepared using hydroxyl ethyl cellulose and poly vinyl alcohol by 
emulsion solvent evaporation method. The particle size and entrapment efficiency 
was found in the range of 200-400 nm and 88.5%- 95.6% respectively. Based on 
the characterization, nanosponges with high entrapment efficiency and least 
particle size were selected for hydrogel formulation. Five different formulations of 
hydrogels were prepared by using carbopol 934 with varying concentration of 
penetration enhancer (propylene glycol) and various evaluation studies were 
carried out. The in vitro release studies revealed that the formulation with higher 
concentration of penetration enhancer (15% propylene glycol) showed greater 
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drug release. From the kinetic study, the best linearity was found with first order 
and Higuchi’s equation [43]. 
 Aldawsari et al.2015) carried out a research aiming to formulate 
lemongrass-loaded ethyl cellulose nanosponges with a topical hydrogel with an 
enhanced antifungal effect and decreased irritation. Lemongrass-loaded ethyl 
cellulose nanosponges were formulated. The emulsion solvent evaporation 
technique was used for the preparation of the nanosponges. The nanosponge 
dispersions were then integrated into carbopol hydrogels (0.4%). The prepared 
formulations were evaluated for particle size, citral content, and in vitro release. 
Results revealed that all the nanosponge dispersions were nanosized, with 
satisfactory citral content and sustained release profiles. Statistical analysis 
revealed that both ethyl cellulose : polyvinyl alcohol ratio and stirring rate have 
significant effects on particle size and percentage released after 6 hours; however, 
the effect of the stirring rate was more prominent on both responses. The selected 
hydrogel formulation, F9, was subjected to surface morphological investigations, 
using scanning and transmission electron microscopy, where results showed that 
the nanosponges possess a spherical uniform shape with a spongy structure, the 
integrity of which was not affected by integration into the hydrogel [44]. 
 Srinivas P. and Jahnavi Reddy A. (2015) formulated controlled release 
Isoniazid (INH) nanosponges for topical delivery. Nanosponges using ethyl 
cellulose polymer were prepared successfully using PVA as surfactant by 
emulsion-solvent evaporation method. The effects of different surfactant 
concentration, drug: polymer ratio, stirring speeds, stirring time and sonication 
time on the physical characteristics of the nanosponges as well as the drug 
entrapment efficiency of the nanosponges were investigated. Particle size analysis 
and surface morphology of nanosponges were performed. The scanning electron 
microscopy of nanosponges showed that they were spherical in shape and spongy 
in nature. The particle size of the formulations was found to be 124 nm and the 
drug entrapment efficiency was found to be in the range of 47.18% to 74.86 %. 
The optimized Nanosponge formulation (I6) was selected for formulating 
nanogels using various gelling agents like Carbopol 934, Carbopol 940, HPMC 
K4M and studied for pH, viscosity and in vitro drug release. Of the various 
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formulations prepared, F2 was found to show the maximum sustained drug release 
of 74.26% in 10 hours [45]. 
  Seema et al. (2015) developed curcumin loaded nanosponges which 
increased the bioavailability and retention time at the colon. Clinical importance 
of curcumin in colon diseases like inflammatory bowel diseases (Chron’s disease 
and ulcerative colitis) irritable bowel syndrome and colon cancer has been 
reported. Due to small size and porous nature of the novel delivery system they 
can easily bind to poorly-soluble drugs within their matrix and prevent drug from 
rapid metabolism and excretion, improve their bioavailability. The nanosponge of 
curcumin is prepared by solvent evaporation method. Further the formulated 
nanosponges are evaluated for its phase solubility, particle size determination, zeta 
potential, SEM, TEM analysis, loading efficiency, and production yield and in 
vitro release study [46].  
 Lockhart et al. (2015) reported the synthesis and encapsulation of 
polyester nanosponge particles (NPs) co-loaded with tamoxifen (TAM) and 
quercetin (QT) to investigate the loading, release and in vitro metabolism of a dual 
drug formulation. The NPs were made in two variations, 4% and 8% crosslinking 
densities, to evaluate the effects on metabolism and release kinetics. The stability 
of the formulation was established in simulated gastrointestinal fluids, and the 
metabolism of TAM was shown to be reduced 2-fold and 3-fold for NP-4%s and 
NP-8%s, respectively, while QT metabolism was reduced 3 and 4-fold. This work 
demonstrates the suitability of the nanosponges not only as a dual release drug 
delivery system but also enabling a regulated metabolism through the capacity of 
the nano network. The variation in crosslinking enables a dual release with 
tailored release kinetics and suggests improved bioavailability aided by a reduced 
metabolism [47]. 
 Wang Y et al., (2014) aimed to identify the CXCR4 antagonists that could 
reduce and/or inhibit tumour metastasis from natural products. C-X-C chemokine 
receptor type 4 (CXCR4) signalling has been demonstrated to be involved in 
cancer invasion and migration; therefore, CXCR4 antagonist can serve as an anti-
cancer drug by pre-venting tumor metastasis. According to the molecular docking 
screening, we reported here silibinin as a novelCXCR4 antagonist. Biochemical 
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characterization showed that silibinin blocked chemokine ligand 12(CXCL12)-
induced CXCR4 internalization by competitive binding to CXCR4, therefore 
inhibiting down-stream intracellular signalling. The inhibition of silibinin was also 
observed in MCF-7/CXCR4 cells rather than MCF-7 cells that express low level 
of CXCR4. This work demonstrated that silibinin is a novel CXCR4 antagonist 
that may have potential therapeutic use for prevention of tumour metastasis [48]. 
 Jana et al. (2014) carried out a study to improve the solubility and 
bioavailability of nebivolol. The present study attempts to overcome these issues 
through nanoparticulate delivery system using widely used carrier EudragitRS100. 
The solvent evaporation (single emulsion) technique was used for developing 
nanoparticles. The impact of formulation and process variables on particle size 
and entrapment efficiency was studied to optimize the formulation. The physico-
chemical characterization confirmed the particle size in nano range with smooth 
and spherical morphology. Further, Fourier transforms infrared (FTIR) 
spectroscopy and differential scanning calorimetry (DSC) studies confirm 
compatibility of drug–polymer combination. The in vitro drug release study of the 
prepared nanoparticles showed prolongation of drug release with reduced burst 
release in comparison with pure drug powder [49]. 
 Sadiq and Abdul Rassol (2014) aimed to develop and evaluate silibinin 
(SIL) loaded solid lipid nanoparticles (SLN) in an attempt to increase its oral 
bioavailability and targeting the lower part of GI tract. Solvent emulsification-
evaporation method with slight modification was used to prepare the SLNs and 
glyceryl monostearate (GMS), trimyristin (TM), tripalmitin (TP) and tristearin 
(TS) were investigated as solid lipid matrix. Tween 20 (T20), tween 80 (T80), 
polyvinyl alcohol (PVA), poloxamer 188 (P188), sodium cholate (SC) and sodium 
deoxycholate (SDC) were investigated as emulsifiers. The formulations were 
evaluated for entrapment efficiency (EE), particle size distribution and in-vitro 
release profile. Furthermore, the optimized formula (F2) was further investigated 
by TEM, FTIR and DSC studies. All the prepared SLNs are within submicronal 
range and acceptable polydispersity index (PI). The EE of the prepared SLNs 
were from (64.67±4.51%) to (87.00±2.00%). FTIR and DSC studies were done 
for the final formula (F2) which contains TS as solid lipid matrix and T80 and 
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P188 as emulsifier combination and it showed no drug – excipient incompatibility 
and suggests formation of an amorphous solid solution. It can be concluded that 
SIL could easily incorporated into SLN containing TS and P188 for oral use [50]. 
 Poojaa et al. (2014) tried to develop silibinin loaded chitosan 
nanoparticles so as to improve its bioavailability. This study presents fabrication 
and characterization of chitosan-tripolyphosphate based encapsulation of silibinin. 
Various preparations of silibinin encapsulated chitosan-tripolyphosphate 
nanoparticles were studied for particle size, morphology, zeta-potential, and 
encapsulation efficiencies. Preparations were also evaluated for cytotoxic 
activities in vitro. The optimized silibinin loaded chitosan nanoparticles were of 
263.7 ± 4.1 nm in particle size with zeta potential 37.4 ± 1.57 mV. Nanoparticles 
showed high silibinin encapsulation efficiencies (82.94 ± 1.82%). No chemical 
interactions between silibinin and chitosan were observed in FTIR analysis. 
Powder X-ray diffraction analysis revealed transformed physical state of silibinin 
after encapsulation. Surface morphology and thermal behaviour were determined 
using TEM and DSC analysis. Encapsulated silibinin displayed increased 
dissolution and better cytotoxicity against human prostate cancer cells (DU145) 
than silibinin alone [51]. 
 Ramteke et al. (2014)  proposed a detailed study about the various 
mathematical models of drug dissolution. When a new solid dosage form is 
developed, it is very important to study drug release or dissolution. The 
quantitative analysis of values obtained in dissolution or release rates is easier 
when mathematical formulae are used to describe the process. The mathematical 
modelling helps to optimize the design of a therapeutic device to yield information 
on the efficacy of various release models. In this paper review of the different 
mathematical models used to determine the kinetics of drug release from drug 
delivery systems such as, zero order, first order, Hixson-Crowell,Higuchi, 
Weibull, Korsemeyer-Peppas, Hopfenberg, Baker-Lonsdale and Gompertz model 
were carried out [52]. 
 Raja et al. (2013) formulated nanosponge loaded with ciprofloxacin 
antibiotic and resulted in sustained release. The drug is acid labile and hence it is 
entrapped with ethyl cellulose for its sustained release. As the drug is made into 
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nanoparticle the density was found to be increased. Among all the formulated 
batches starting from F1 through F5 the final batch (F5) is considered as the best 
entrapped (90.80%) nanosponge with greater percentage drug release (99.4%). 
The characterization by SEM concluded the appearance as a nanosponge [53]. 
  Srinivas and Sreeja (2013) produced controlled release Voriconazole 
nanosponges for topical and oral delivery. Nanosponges using three different 
polymers ethyl cellulose, Poly (methyl methacrylate) and Pluronic F-68 
(poloxamer 188) were prepared successfully using PVA as surfactant by emulsion 
solvent evaporation method. The effects of different drug: polymer ratios, 
surfactant concentration, stirring speeds and time, sonication time on the physical 
characteristics of the nanosponges as well as the drug entrapment efficiency of the 
nanosponges were investigated. Particle size analysis and surface morphology of 
nanosponges were performed. The scanning electron microscopy of nanosponges 
showed that they were spherical in shape and spongy in nature. The particle size 
of the optimized formulations was in the range of 200-400nm and the drug 
entrapment efficiency was found to be in the range of 69.8 % to 72.5%. These 
nanosponge formulations were prepared as gel using carbopol 971P and studied 
for pH, viscosity, in vitro drug release, antimicrobial activity. Among the various 
formulations prepared E2, P2 and F2 were found to show the maximum drug 
release of 92.76%, 91.84% and 95.88% respectively at 1:2 drug: polymer ratio at 
the end of 48 hours [54]. 
 Yeol Yang et al. (2013) developed a novel silymarin-loaded solid 
nanoparticle system using Shirasu porous glass (SPG) membrane emulsification 
and a spray-drying technique. The physicochemical characteristics of these 
nanoparticles were determined by scanning electron microscopy, differential 
scanning calorimetry, and powder X-ray diffraction. Their dissolution, 
bioavailability, and hepatoprotective activity in rats were assessed by comparison 
with a commercially available silymarin-loaded product. Formulation of a 
silymarin-loaded nanoemulsion, comprising silymarin, castor oil, 
polyvinylpyrrolidone, Transcutol HP, Tween 80, and water at a weight ratio of 
5/3/3/1.25/1.25/100 was accomplished using an SPG membrane emulsification 
technique at an agitator speed of 700 rpm, a feed pressure of 15 kPa, and a 
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continuous phase temperature of 25°C. This resulted in generation of 
comparatively uniform emulsion globules with a narrow size distribution. 
Silymarin was located in unaltered crystalline form in the nanoparticles. The drug 
dissolved rapidly from the nanoparticles, reaching nearly 80% within 15 minutes, 
indicating three-fold better dissolution than that of the commercial product [55]. 
 Ying Ho et al. (2012) investigated the in vitro and in vivo bioactivities of 
silibinin (SB), paclitaxel (PTX) and SB and PTX in combination (SB+PTX) 
against murine metastatic mammary 4T1 cancer cell line. Isobologram and 
combination index (CI) analyses showed that SB and PTX can function 
synergistically in the inhibition of 4T1 cell proliferation with a CI value < 1. Flow 
cytometry and Western blot analyses demonstrated that both drugs deregulated 
cell-cycle mediators and induced apoptosis in 4T1 cells. A real-time in vivo 
bioluminescence imaging system to monitor the breast cancer cell metastasis and 
in vivo study indicated that SB co-treated with PTX can significantly suppress 
lung metastasis of 4T1 cells likely through inhibiting cell proliferation and 
angiogenesis. Together, this study demonstrates that SB could act synergistically 
with PTX in 4T1 cells, providing a therapeutic option for highly metastatic triple 
negative breast cancer [56]. 
 Fehér and Lengyel (2012) studied the activity of silymarin also called as 
milk thistle in liver diseases and also chemopreventive effect. Liver cirrhosis, non-
alcoholic fatty liver and steatohepatitis are risk factors for hepatocellular 
carcinoma (HCC). The silymarin exerts membrane-stabilizing and antioxidant 
activity, it promotes hepatocyte regeneration; furthermore it reduces the 
inflammatory reaction, and inhibits the fibrogenesis in the liver. These results 
have been established by experimental and clinical trials. According to open 
studies the long-term administration of silymarin significantly increased survival 
time of patients with alcohol induced liver cirrhosis [57]. 
 Das S. et al. (2011) formulated silymarin nanoparticles by 
nanoprecipitation in polyvinyl alcohol stabilized Eudragit RS100® polymer. 
Process parameter optimization provided 67.39% entrapment efficiency and a 
Gaussian particle distribution of average size 120.37 nm. Silymarin release from 
the nanoparticles was considerably sustained for all formulations.  Silymarin 
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nanoparticles were strongly protective against hepatic damage when tested in a 
paracetamol overdose hepatotoxicity model. Nanoparticles recorded no animal 
death even when administered after an established paracetamol-induced hepatic 
necrosis [58]. 
 Zhang Y et al. (2010) gave details regarding different mathematical 
approaches that have been proposed to assess the similarity between two drug 
dissolution profiles particularly DD solver. The purposes of this article were: (1) 
to describe the development of a software program, called DD Solver, for 
facilitating the assessment of similarity between drug dissolution data; (2) to 
establish a model library for fitting dissolution data using a nonlinear optimization 
method; and (3) to provide a brief review of available approaches for comparing 
drug dissolution profiles.  Sample runs of the program demonstrated that the 
results were satisfactory, and DD Solver could be served as a useful tool for 
dissolution data analysis [59]. 
 Zhanga et al. (2009) successfully prepared micronized silybin particles by 
emulsion solvent diffusion method. Uniform spherical and rod-shaped particles 
could be obtained using sodium dodecyl sulfate (SDS) concentration of 0.1 wt% 
at 30 and 15⁰C, respectively. The characterization of silybin particles by SEM and 
particle size distribution (PSD) indicated that with the increase of temperature 
from 15 to 30⁰C, the prepared particles became bigger and had a tendency to turn 
into spherical shapes; with the increase of SDS concentration from 0.02 - 0.1 wt%, 
the span of PSD became narrower while the mean particle size kept almost 
unchanged. XRD patterns and FT-IR spectra showed that the spherical and rod-
shaped silybin particles possessed decreased crystallinity; however, the chemical 
structure and components were similar to those of the commercial silybin powder. 
Dissolution tests demonstrated that both of the spherical and rod-shaped silybin 
particles exhibited significantly enhanced dissolution rate when compared to the 
commercial silybin powder [60]. 
 Snehalatha et al. (2008) prepared etoposide-loaded nanoparticles  using 
nanoprecipitation and emulsion solvent evaporation techniques using polylactide-
co-glycolic acid and poly(ε-caprolactone) in presence of Pluronic F68, 
respectively. Effect of formulation variables like stabilizer concentration, amount 
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of polymer, and drug was studied. The methods produced nanoparticles with good 
entrapment efficiency of around 80%. Recovery of nanoparticles was as high as 
95% and drug content was around 1.5%. Increase in lactide content decreased the 
release of etoposide in vitro and poly(ε- caprolactone) nanoparticles retarded 
etoposide release for 48 hr [61]. 
 Mahmoud et al. (2006) formulated silymarin hybrid liposomes for buccal 
administration after investigating their stability and in vivo hepatoprotective 
efficiency. Silymarin loaded hybrid liposomes composed of lecithin (L), 
cholesterol(Ch), stearyl amine (SA) and Tween 20 (T20) in molar ratio of 
(9:1:1:0.5) were prepared. Their stability upon storage was studied at 4 ◦C and at 
ambient conditions. Stored samples were analysed for percent encapsulation, drug 
release, particle size, turbidity measurement and visual changes. Characterization 
of the blend between phospholipid and silymarin was done using FT-IR and DSC 
which indicated a possible interaction. The stabilized formula of silymarin hybrid 
liposomes was evaluated upon buccal administration regarding its 
hepatoprotective activity against carbon tetrachloride-induced oxidative stress in 
albino rats. The introduced silymarin hybrid liposomes produced a significant 
decrease in both transaminase levels when challenged with CCl4 (intraperitonially) 
in comparison with orally administered silymarin suspension [62]. 
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AIM AND OBJECTIVE 
 To formulate silymarin nanosponges so as to target cancer cells 
particularly breast cancer, colorectal cancer using different polymers. 
 To increase the bioavailability of silymarin by developing silymarin 
nanosponges. 
 To reduce the dose, dosing frequency and to reduce dose dependent side 
effects of Silymarin. 
  To facilitate drug targeting or selective uptake of drug. 
 Deliver the drug at the specified site in a controlled manner without 
showing any burst effect. 
 
To achieve this objective the following steps were carried out: 
 The preformulation studies. 
 Formulation of silymarin nanosponges and its optimization by general full 
factorial design. 
 Characterisation of the prepared silymarin nanosponges. 
 In-vitro evaluation of silymarin nanosponges. 
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PLAN OF WORK 
 
 
 Preformulation Studies 
Construction of 
calibration curve 
FT-IR Compatibility 
studies 
Formulation of Silymarin Nanosponges  
Preparation of nanosponges of silymarin using 2 
different polymers(ethyl cellulose, eudragit) using 
emulsion solvent diffusion method 
Characterisation of Silymarin Nanosponges 
 Particle size determination             SEM 
  Zeta potential                                     Entrapment efficiency 
Solubility 
studies 
Optimization and Evaluation of Silymarin Nanosponges 
In vitro release study 
In vitro drug release 
kinetics 
Optimization of Silymarin 
nanosponges by general full 
factorial design 
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MATERIALS AND EQUIPMENTS 
MATERIALS USED 
Sl. No Materials Source 
1. Silymarin Gift sample 
2. Ethyl Cellulose Himedia, Mumbai 
3. Eudragit Yarrow Pharma 
4. Polyvinyl Alcohol Sigma Aldrich 
5. Ethanol Zhuhai Chemico  Industries 
6. Di-Sodium Hydrogen Orthophosphate SD Fine Chemical Limited 
7. 
Potassium Dihydrogen 
Orthophosphate 
Qualigens Fine Chemicals, 
Mumbai 
 
EQUIPMENTS USED 
Sl. No Equipment Model/ Company 
1. Magnetic Stirrer REMI-2MLH 
2. Optical Microscope MOTIC B1 SERIES 
3. UV Spectrophotometer JASCO V-530 
4. FT-IR Spectrometer FTIR JASCO -4100 
5. pH Meter pH TESTER 1,2(EUTECH) 
6. Zeta Sizer MALVERN 
7. SEM 
HITACHI X650, Tokyo, 
Japan 
8. Dialysis membrane 50mm Himedia, Mumbai 
 
SOFTWARE USED 
Minitab 18                                            :  Minitab INC, USA 
DD Solver                                             : Microsoft 
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DRUG PROFILE 
SILYMARIN 
Description: 
Silymarin is an active component obtained from the plant Silybum marianum, 
commonly known as milk thistle from the family Asteraceae. About 70-80% of 
the plant consists of silymarin flavinolignan i. e silidianin, silychristin, silybin A 
and B and iso silybin A and B. 
IUPAC name: 2-(2,3-Dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxyl 
methyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyean-4-
one. 
Empirical formula: C25H22O10 
Chemical structure: 
 
 
Molecular weight: 482.436 
Melting point: 164-174°C 
Boiling point: 793°C at 760mm Hg 
Density: 1.527g/cm3 
Colour: light yellow powder 
Solubility: solubility of silymarin in various solvents is given in Table 2. 
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Table 2: Solubility of Silymarin in Various Solvents 
Transcutol 350.1 mg/ Ml 
Ethanol 225.2 mg/ mL 
Polysorbate 20 131.3 mg/ mL 
Glyceryl monooleate 33.2 mg/ mL 
Water 0.04 mg/ mL 
  
Categories: 
Hepatoprotective, antioxidative, anti -inflammatory, neuroprotective, neurotropic, 
antilipid peroxidative, cardioprotective and membrane stabilizing agent. 
Mechanism of Action: 
 Silymarin due to its property of free radical scavenging can act against 
lipid per oxidation and also helps to increase cellular content of 
Glutathione. 
 During xenobiotic damage it regulates membrane permeability resulting in 
better membrane stability. 
 Silymarin has asteroid like effect which helps in regulating nuclear 
expression. The conversation of stellate hepatocytes to myofibroblast 
which is known factor for cirrhosis is inhibited by silymarin. 
Adverse Reactions: 
Nausea, diarrhoea, indigestion, flatulence, bloating, fullness or pain, anorexia, 
occasional laxative effects. It is well-known to cause allergic response in people 
who are sensitive to Asteraceae/ Compositae family. 
Dosage and administration: 
Oral; hepatic diseases: adult 70-140mg bid/tid 
Absorption: 
Absorption of silymarin is comparatively low after oral administration i.e about 
20-30%. Peak plasma concentrations are achieved within 4-6 hrs. 
Metabolism: 
In the liver silymarin gets conjugated with sulphates and glucuronic acid and then 
conjugates passes through plasma and bile. 
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Elimination: 
Silymarin is mainly excreted in bile and to lesser extent in urine. The elimination 
half -life is silymarin is 1-3 hrs. 
Indications: 
Silymarin is used to treat hepatitis, as an adjunctive therapy in the treatment of 
cirrhosis, jaundice and also in alcohol related liver diseases.  It has also found to 
possess anticancer activity. 
Contraindications: 
Silymarin is contraindicated in cases of hypersensitivity, hepatic encephalopathy, 
and primary biliary cirrhosis and in cases of hypersensitivity to components of 
silymarin. 
Storage and Handling: 
Store in a well closed container in a cool, dry and dark place. 
Brand names: 
Silymarin marketed product given in Table 3. 
 
Table 3: Marketed Products of Silymarin 
Brand names Manufacturer’s 
C. Hepasil Signova 
C. Levalon Micro B&B 
C.Levalon Serum Intl. 
C.Prohepforte LUPIN 
C.Silimar Zydus(G.Rem) 
C.Sison Dr. Alson Labs 
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EXCIPIENT PROFILE 
 
POLYVINYL ALCOHOL  
Synonyms 
Airvol, elvanol, gohsenol, PVA, vinyl alcohol polymer 
Chemical Name and CAS Registry Number  
Ethanol, homopolymer [900-89-5] 
Empirical Formula 
(C2H4O)n 
Chemical Structure 
 
Molecular Weight: 
20000-200000 
 Polyvinyl alcohol is a water soluble synthetic polymer represented by 
formula (C2H4O)n.  The value of n for commercially available material lies 
between 500 and 5000, equivalent to a molecular weight range of approximately 
20000-200000. 
 
Table 4: Commercially Available Grades of Polyvinyl Alcohol 
Grade Molecular Weight 
High viscosity 200000 
Medium viscosity 130000 
Low viscosity 20000 
  
Functional Category 
Coating agent, lubricant, stabilizing agent and viscosity increasing agent. 
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Application on Pharmaceutical Formulation  
Polyvinyl alcohol is used primarily in topical pharmaceutical and ophthalmic 
formulation. It is used as a stabilizing agent for emulsions (0.25-3.0%w/v).  
Polyvinyl alcohol is also used as viscosity-increasing agent for viscous 
formulations such as ophthalmic products.  It is used in artificial tears and contact 
lens solution for lubrication purpose, in sustained-release formulation for oral 
administration, and in transdermal patches. 
Table 5:  Uses of Polyvinyl Alcohol 
Uses Concentration 
Emulsions 0.5% 
Ophthalmic formulations 0.25-3.00% 
Topical solutions 2.5% 
Description 
 Polyvinyl alcohol occurs as an odourless, white to cream-colored granular 
powder. 
Typical Properties 
Melting point: 
 228⁰C for fully hydrolysed grades 
 180⁰C-190⁰C for partially hydrolysed grades 
Refractive Index 
nD25=1.49-1.53 
Solubility 
PVA is soluble in water and insoluble in organic solvents.  Dissolution requites 
dispersion (wetting) of the solid in water at room temperature followed by heating 
the mixture to about 90°C for approximately 5 mins.  Mixing should be continued 
while the heated solution is cooled to room temperature. 
 
Specific Gravity  
 1.19-1.31 for solid at 25⁰C   
 1.02 for 10% w/v aqueous solution at 25⁰C 
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Viscosity (Dynamic) 
Table 6: Viscosity of Commercial Grades of Polyvinyl Alcohol  
Grade Dynamic Viscosity of 4%w/v Aqueous 
Solution at 200°C (Mpas) 
High viscosity 40.0-65.0% 
Medium viscosity 21.0-33.0% 
Low viscosity 4.0-7.0% 
 
Stability and Storage Conditions 
Polyvinyl alcohol is stable when stored in tightly sealed container in a cool, dry 
place.  Aqueous solutions are stable in corrosion resistant sealed containers.  
Preservatives may be added to the solution if extended storage is required.  
Polyvinyl alcohol undergoes slow degradation at 100⁰C and rapid degradation at 
200⁰C; it is stable on exposure to light. 
Incompatibilities 
Polyvinyl alcohol undergoes reactions typical of a compound with secondary 
hydroxyl groups such as esterification.  It decomposed in strong acid and softens 
or dissolves in weak acids and alkalis.  It is incompatible at high concentration at 
high concentration with inorganic salts, especially sulphates and phosphates, 
precipitation of polyvinyl 5% w/v can be caused by phosphates, gelling of 
polyvinyl alcohol solution may occur if borax is present . 
Method of Manufacture 
Polyvinyl alcohol is produced through the hydrolysis of polyvinyl acetate.  The 
repeating unit of vinyl alcohol is not used as the starting material because it can’t 
be obtained in the quantities and the purity required for polymerization purposes.  
The hydrolysis proceeds rapidly in methanol, ethanol, or a mixture of alcohol and 
methyl acetate, using alkalis or mineral acids or catalysis. 
Safety 
 Polyvinyl alcohol is generally considered a non-toxic material.  It is non-
irritant to the skin and eyes at concentration up to 10% concentration upto 7% are 
used in cosmetics. 
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ETHYL CELLULOSE 
 
Nonproprietary names 
BP : Ethylcellulose 
PhEur : Ethylcellulosum 
USPNF : Ethylcellulose 
Synonyms 
Aquacoat; E462; Ethocel; Surlease 
Chemical names and CAS registry number 
Cellulose ethyl ether [9004-57-3] 
Empirical formula 
Ethyl cellulose is an ethyl ether of cellulose, a long chain polymer consisting of 
anhyroglucose units joined by acetate linkage. Each anhydroglucose units has 
three replacable hydroxyl groups which are substituted to the extent of 2.25-2.60 
ethoxul groups(OC2H5) per unit, equivalent to an ethoxyl content of 44-51% 
Structural formula 
 
Functional category 
Coating agent; tablet binder; viscosity increasing agent 
Applications in pharmaceutical formulation or technology 
Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. 
The main use of ethyl cellulose in oral formulations is as a hydrophobic coating 
agent for tablet and granules. 
Ethyl cellulose coatings are used to modify the release of a drug, to mask an 
unpleasant taste, or to improve the stability of the formulations. Higher viscosity 
ethyl cellulose grades tend to produce stronger, tougher films. Ethyl cellulose is 
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also widely used in drug microencapsulation, high viscosity grades usually being 
used. 
Description 
Ethyl cellulose is a tasteless, free flowing, white or light tan coloured powder. 
Typical properties 
Density:  
 0.4g/cm3 
Glass transition temperature:  
130-133⁰C 
Melting point: 
 165-173⁰C 
Hygroscopicity: 
Ethyl cellulose absorbs very little water at high relative humidity or during 
immersion. 
Solubility: 
Practically insoluble in glycerine, propylene glycol and water. Ethyl cellulose that 
contain not less than 46.5% of ethoxyl group is freely soluble in chloroform, 
ethanol, ethyl acetate, methanol and toluene. 
Specific gravity: 1.12-1.15 
Viscosity: 
Various grades of ethyl cellulose are commercially available having viscosities 
ranging from 3-385MPas. 
Stability and storage conditions 
Ethyl cellulose is a stable, slightly hygroscopic material. It is chemically resistant 
to alkalis, both dilute and concentrated, and to salt solutions, though it is more 
sensitive to acidic materials than cellulose esters. Ethyl cellulose is subject to 
oxidative degradation in the presence of sunlight or UV light at elevated 
temperatures. 
The bulk material must be stored in a dry place, in a well closed container at a 
temperature between 7-32⁰C. 
Incompatibilities 
Incompatible with paraffin wax and microcrystalline wax. 
Excipient Profile 
 
Department of Pharmaceutics  42 
 
Method of manufacture 
Ethyl cellulose is prepared from wood pulp by treatment with alkali followed by 
ethylation of alkali cellulose with chloroethane. 
Safety 
Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. It 
is also used in food products. It is generally regarded as a nontoxic, non-allergenic 
and non-irritant material. 
Handling precautions 
Observe normal precautions appropriate to the circumstances and quantity of 
materials handled. Dust may be irritant to the eyes and eye protectant should 
therefore be worn. Ethyl cellulose is combustible. 
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EUDRAGIT 
 
Chemical name: methacrylic acid 
Chemical formula:  C4H6O2 
Chemical Structure: 
 
 
Synonyms: 
 2-(methoxycarbonyl)-1-propene 
 2-methyl-2-propenoic acid methyl ester 
Appearance: 
Colourless 
Odour: 
Unpleasant, acrid and repulsive. 
Solubility: 
Soluble in warm water 
Miscible with most organic solvents 
Density: 
1.02g/cm3 
Molar mass: 
86.06g/mol 
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Boiling point: 
161⁰C 
Melting point: 
15⁰C 
Applications 
Ophthalmic drug delivery 
Buccal and sublingual drug delivery 
Gastrointestinal drug delivery 
Intestinal drug delivery 
Colon drug delivery 
Transdermal drug delivery 
Vaginal drug delivery 
Gene drug delivery 
Vaccine drug delivery   
Eudragit polymer were selected for this studies because they dissolved at pH > 5.5 
and are not soluble in acidic gastric fluid and which can prevent  the premature 
release of the incorporated drug molecule during the preparation before dosing. 
Eudragit are sufficiently being used in pre-clinical models to enable in vivo safety 
pharmacology studies where small changes in organ function and physiology are 
assessed during lead optimization. 
Method of Manufacture 
In one route, acetone cyanohydrin is converted to methacrylamide sulphate using 
sulphuric acid which is then hydrolysed to methacrylic acid. In the second route, 
isobutylene or tert-butanol are oxidised to methacrolein, then  methacrylic acid. 
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EXPERIMENTAL METHODS 
 
I. PREFORMULATION STUDIES: 
Physical characteristics: 
By visual examination the drug was tested for its physical characters like 
colour, odour and texture.  
Solubility test: 
Silymarin powder (about 1mg) was taken in a test tube and solubility in 
ethanol, water, dichloromethane and chloroform was tested.  
Preparation of stock solution  
The standard stock solution of silymarin was prepared by transferring 
accurately weighed quantity (10 mg) of silymarin raw material in 100 ml of 
volumetric flask. The drug was dissolved in few ml of ethanol and the volume was 
made up to 100 ml with ethanol to get a stock solution of 100 μg/mL.  
Selection of Wavelength 
The standard stock solution was scanned in the range of 200 to 400 nm in 
UV spectrophotometer using phosphate buffer pH 6.8 as blank. The absorption 
maximum was found at 288 nm. 
Construction of calibration curve of silymarin: 
From the standard stock solution of silymarin 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 
4 ml were withdrawn to 10 ml volumetric flask and then made up volume with 
phosphate buffer pH 6.8 to get a concentration range of 5-40 μg/mL. The 
absorbance of these solutions was measured at 288nm using JASCO V-530 UV 
1600 UV- visible spectrophotometer. Phosphate buffer pH 6.8 was used as blank.  
The calibration curve was plotted between concentration and absorbance [63]. 
 
Preparation of Buffer Solutions 
Phosphate buffer pH 6.8: An accurately weighed quantity of 28.80gm of 
disodium hydrogen phosphate and 11.45gm of potassium dihydrogen phosphate 
was dissolved in sufficient water to produce 1000ml. 
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Drug Excipient Compatibility Studies 
FT-IR spectrum of drug was recorded using FT-IR Spectro photometer 
(Shimadzu JASCO 4100). The diffuse reflectance technique was utilised in the 
mid IR 4000-400 cm-1 spectral region. The procedure consist of dispersing the 
sample in KBr(100mg) using a mortar, triturating the materials into a fine powder 
bed into the holder using compression gauge. The pressure was around 5 tons for 
5 minutes. The pellet was placed in the light path and the spectrum was recorded. 
The characteristic peaks of the functional groups were interpreted. 
The FTIR spectrum of silymarin, polymers ethyl cellulose and eudragit were 
recorded. The spectrum of physical mixture of silymarin, polymer and co-polymer 
were also documented to check for their compatibility. 
 
 
II. FORMULATION OF SILYMARIN NANOSPONGES BY EMULSION 
SOLVENT DIFFUION METHOD: 
Emulsion solvent diffusion method was used to formulate silymarin loaded 
nanosponges by using a suitable polymer. Dispersed phase consists of specified 
amount of drug and polymer which was dissolved in 20 ml of an organic solvent, 
dichloromethane. Aqueous phase consists of specified amount of poly vinyl 
alcohol dissolved in 100 ml distilled water. Disperse phase was added drop by 
drop into aqueous phase by stirring on magnetic stirrer at 1000 rpm for about 2 
hours. The nanosponges formed were collected by filtration and dried in oven at 
40°C for about 24 hours. They were then kept in the vacuum desiccators to 
remove the residual solvent. The silymarin nanosponges were formulated using 
polymers ethyl cellulose and eudragit [30]. 
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III. CHARACTERIZATION OF NANOSPONGES 
FTIR Spectroscopy of Nanosponges 
Before formulating a drug substance into dosage form, it is essential that it 
should be chemically and physically compatible. Compatibility studies give 
information needed to define the nature of the drug substance and provide a frame 
work for the drug combination with pharmaceutical excipients in the fabrication 
of a dosage form. This study was carried out by using infrared spectrophotometer 
to find if there is any possible chemical interaction between the silymarin and 
polymers. 
A few mg of sample (silymarin nanosponges) was weighed and mixed 
with 100 mg of potassium bromide (dried at 40-50°C). The mixture was taken and 
compressed under 10- ton pressure in hydraulic press to form a pellet. The pellet 
was scanned from 4000-400 cm-1 in IR spectrophotometer.  
Determination of Percentage Yield 
Silymarin loaded nanosponges were weighed after drying. Percentage 
yield was calculated by 
 
% 𝑦𝑖𝑒𝑙𝑑 =  
𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑠𝑝𝑜𝑛𝑔𝑒𝑠 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡( 𝑑𝑟𝑢𝑔 + 𝑝𝑜𝑙𝑦𝑚𝑒𝑟𝑠)
× 100 
 
 Scanning Electron Microscopy (SEM) 
SEM analysis was performed to determine their microscopic characters 
(shape & morphology) of prepared silymarin nanosponges. Nanosponges were 
prepared and dried well to remove the moisture content and images were taken 
using scanning electron microscopy (Hitachi X650, Tokyo, Japan) in different 
magnifications .Samples were placed on glass slide kept under vacuum and then 
by using sputter coater unit, samples were coated with a thin gold layer, operated 
at 15kv acceleration voltage [30]. 
Particle Size Determination  
The average mean diameter and size distribution of loaded nanosponges is  
found by Dynamic Light Scattering method using Malvern zeta sizer at 25°C.The 
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dried nanosponges were dispersed in water to obtain proper light scattering 
intensity for silymarin nanosponges [43]. 
Determination of Zeta Potential  
Zeta potential is a measure of surface charge. The surface charge 
(electrophoretic mobility) of nanosponge can be determined by using Zeta sizer 
(Malvern Instrument) having zeta cells, polycarbonate cell with gold plated 
electrodes and using water as medium for sample preparation. It is essential for 
the characterisation of stability of the nanosponges [45].  
Determination of Entrapment Efficiency  
The entrapment efficiency of nanosponges were determined by adding    
10 ml of phosphate buffer of pH 6.8 and sonicated in a bath sonicator and filtered. 
1 ml of filtrate is made up to 10 ml with phosphate buffer and was assayed 
spectrophotometrically at 288 nm (UV visible spectrophotometer, model         
UV-1601 PC, Shimadzu). The amount of entrapped drug was calculated from the 
equation [43]. 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 
 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 
  ×  100 
  In Vitro Release Studies   
Drug release was determined by dialysis method; two ml of each 
formulation (test and control) were poured into dialysis bags and put into 25 ml 
phosphate buffer (pH 6.8) and stirred (100 rpm, room temperature). At 
predetermined time intervals, 2 ml of phosphate buffer was taken and then 
substituted by fresh phosphate buffer. Finally, the amounts of released silibinin in 
phosphate buffer were measured by spectrophotometer at 288 nm [40]. Aliquots 
withdrawn were assayed at each time interval for the drug released at λ max of   
288 nm using UV‐Visible spectrophotometer by keeping phosphate buffer pH 6.8 
as blank and the amount of released drug was estimated by the standard curve[30]. 
Optimization 
The formulation of silymarin nanosponges is optimized by general full 
factorial design. The type of polymer and concentration of polymer are considered 
as independent variables and the percentage drug released is considered as 
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dependent variable. Minitab 18 Software (Minitab Inc, USA) is used for this 
purpose. 
In Vitro Drug Release Kinetics 
The drug release kinetics of Silymarin nanosponges was determined by plotting 
the following kinetic models, using the data collected from in vitro release studies 
( zero order, first order and Higuchi equations). The mechanism of drug release 
was determined by using Korsmeyer-Peppas equations [59]. 
Zero-Order Kinetics: 
 Cumulative amount of drug released was plotted against time.  
C = K0t  
 Where K0 is the zero-order rate constant expressed in units of concentration/time 
and t is the time in hours. A graph of concentration vs. time would yield a straight 
line with a slope equal to K0 and intercept the origin of the axis. This kinetics 
describes concentration independent drug release from the formulations. 
First order kinetics:  
First order graph is plotted by log cumulative percentage of drug remaining vs. 
time. This kinetics describes concentration dependent drug release from the 
formulations.   
Log C = Log Co + Kt / 2.303 
Where C0 is the initial concentration of drug, k is the first order constant, and t is 
the time. 
Higuchi’s Model:  
Higuchi’s model as cumulative percentage of drug released vs. square root of 
time.  
Q = Kt1/2 
Where K is the constant reflecting the design variables of the system and t is the 
time in hours. This model describes the release of drug on the basis of Fickian 
diffusion as a square root of time dependent process from swellable matrix. 
Korsmeyer-Peppas Equations:  
The mechanism of drug release, the first 60% of drug release were plotted in 
Korsmeyer et al’s equation log cumulative percentage of drug released vs. log 
time, and the exponent n was calculated through the slope of the straight line, 
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Mt / M∞ = Ktn 
Where Mt/M∞ is the fractional solute release, t is the release time, K is a kinetic 
constant characteristic of the drug/polymer system, and n is an exponent that 
characterizes the mechanism of release of tracers. This type of drug release is 
controlled by combination of polymer swelling, erosion and diffusion through 
hydrated matrix. The mechanism of diffusion is identified from the values of ‘n’. 
 The value of n ≤ 0.45 indicating fickian diffusion(Case I) 
 The value of n between 0.45 to 0.89(0.45<n<0.89) indicating non fickian 
(anomalous) diffusion. Here release is controlled by combination of 
diffusion and polymer relaxation. 
 The value of n =0.89, indicating the zero order release or case 2 transport. 
Here the drug release rate is independent of time and involves polymer 
relaxation. 
 The value of n > 0.89, indicating the super case 2 transport. 
Kinetic study was performed using DD solver software. 
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RESULTS AND DISCUSSION 
I. PREFORMULATION STUDIES 
Physical Characteristics 
Silymarin was checked for its colour, odour and texture. Silymarin is light yellow 
coloured powder in appearance, odourless and amorphous in nature. 
Solubility 
Solubility test for Silymarin was carried out in different solvents such as ethanol, 
water, dichloromethane and chloroform and results are given in Table 7. 
Table 7: Solubility test for Silymarin in different solvents 
 
Selection of Wavelength 
The Silymarin stock solution of concentration 100µg/mL was scanned in the range 
of 200-400nm for λmax.  using double beam UV Spectrophotometer. The 
absorption peak obtained is shown in Figure 4.  
 
Figure 4:   UV spectra of Silymarin 
Sl. No Solvent Soluble Sparing Soluble Insoluble 
1. Ethanol   - - 
2. Dichloromethane   - - 
3. Chloroform -   - 
4. Water - -   
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The maximum absorption of Silymarin was found to be at 288nm and hence it is 
selected as the wavelength for further studies. 
Construction of calibration curve of Silymarin  
In the calibration curve, linearity was obtained between 5-40 µg/ml concentration 
of Silymarin and the regression value was found to be r2 = 0.9996. Hence we can 
conclude that Silymarin obeys Beer Lambert’s Law at the concentration between 
5-40 µg/ml. The results are shown in Table 8 and Figure 5. 
 
Table 8: Concentration and absorbance values for estimation of Silymarin  
 
 
  
Figure 5: Calibration graph of Silymarin 
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Concentration(µg/ml) 
r2 = 0.999 
Sl. No Concentration (µg/ml) Absorbance(AU) at 288nm 
1. 5 0.1686 
2. 10 0.3624 
3. 15 0.5357 
4. 20 0.6963 
5. 25 0.8770 
6. 30 1.0693 
7. 35 1.2700 
8. 40 1.4516 
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Excipient Compatibility Studies 
Fourier Transform Infrared (FT-IR) spectra of the samples were obtained using a 
FTIR Jasco 4100 Spectrometer by KBr disc method. The spectrums were recorded 
for the pure drug and physical mixture of drug and polymer and are shown in 
Figures 6,7,8,9,10,11and 12.  
 
 
                    Figure 6: FTIR spectrum of Silymarin 
 
    Table 9: FTIR interpretation of Silymarin 
Materials Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional group 
assignment 
 
 
SILYMARIN 
3650-3200 3410.49 
3625.52 
OH stretching 
1820-1665 1643.05 C=O stretching 
1320-1210 1273.75 C-O-C stretching 
1161-1029 1121.4 In plane =C-H 
bending 
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Figure 7: FTIR spectrum of Ethyl Cellulose 
 
Table 10: FTIR interpretation of Ethyl Cellulose 
Materials 
Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional 
group 
assignment 
ETHYL 
CELLULOSE 
3650-3200 3647.7 O-H stretching 
2960-2850 2974.66 C-H stretching 
1820-1665 1734.66 C=O stretching 
1680-1620 1647.88 C=C stretching 
1300-1000 1118.51 C-O stretching 
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Figure 8: FTIR spectrum of Eudragit 
 
 
Table 11: FTIR interpretation of Eudragit 
Materials 
Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional 
group 
assignment 
EUDRAGIT 
3000-3700 3430.74 O-H stretching 
1500-1800 1720.19 N-H bending 
2700-3300 2995.87 C-H stretching 
1300-1500 
1451.17 
1386.57 
C-H bending 
1000-1300 
1262.18 
1159.01 
C-O stretching 
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Figure 9: FTIR spectrum of Poly Vinyl Alcohol (PVA) 
 
 
Table 12: FTIR interpretation of Poly Vinyl Alcohol 
Materials 
Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional group 
assignment 
POLYVINYL 
ALCOHOL 
3300-3600 3584.06 OH stretching 
2850-2970 2862.37 CH3 stretching 
1500-1760 1600.63 COOH 
1340-1470 1383.68 Alkanes bending 
1000-1300 1116.58 C-O stretching 
600-800 
757.888 
648.929 
C-H rocking 
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Figure 10: FTIR spectrum of physical mixture containing Silymarin, EC and 
PVA 
 
Table 13: FTIR interpretation of physical mixture containing Silymarin, EC 
and PVA 
 
Materials 
Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional group 
assignment 
MIXTURE 
CONTAINING 
SILYMARIN, 
PVA and EC 
3650-3200 
3644.88 
3613.95 
OH stretching 
2970-2850 2965.98 C-H stretching 
1725-1665 1643.05 C=O stretching 
1320-1210 1273.75 C-O-C stretching 
1161-1029 1124.3 
In plane =C-H 
bending 
800-600 
816.706 
648.929 
C-H rocking 
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Figure 11: FTIR spectrum of physical mixture containing Silymarin, 
Eudragit and PVA 
 
Table 14: FTIR interpretation of mixture containing Silymarin, Eudragit and 
PVA 
Materials 
Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional group 
assignment 
MIXTURE 
CONTAINING 
SILYMARIN, 
EUDRAGIT and 
PVA 
3650-3200 
3642.87 
3423.033 
OH stretching 
3300-2700 2999.73 C-H stretching 
1820-1665 1718.26 C=O stretching 
1800-1500 1639.2 N-H bending 
1500-1300 1386.57 C-H bending 
1320-1210 1268.93 C-O-C stretching 
1161-1029 1161.9 
In plane =C-H 
bending 
800-600 
814.777 
658.571 
C-H rocking 
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The peaks present in the FTIR spectra of pure Silymarin are present in the FTIR 
spectra of physical mixture containing Silymarin with ethyl cellulose and 
Silymarin with eudragit. It is therefore evident that the Silymarin is compatible 
with the excipients ethyl cellulose, eudragit and poly vinyl alcohol and can be 
chosen for the formulation of Silymarin nanosponges.  
 
II. FORMULATION OF NANOSPONGES 
Selection of polymers for the formulation of Silymarin nanosponges by emulsion 
solvent diffusion method was based on the trial batches carried out by using 
different polymers such as ethyl cellulose, eudragit, sodium alginate, HPMC, 
carbopol, hydroxyl ethyl cellulose, chitosan and pectin and the details are depicted 
in Table 15. Drug: polymer ratio was selected based on the literature. The results 
indicated that ethyl cellulose and eudragit was found to be suitable for the 
formulation of Silymarin nanosponges. 
 
Table 15: Trial batches for formulation of Silymarin nanosponges 
Drug Polymer Ratio Result Observed 
SILYMARIN 
Ethyl cellulose 1:2 Product obtained 
Eudragit 1:2 Product obtained 
Hydroxy propyl methyl cellulose 1:2 Less yield 
Hydroxyl ethyl cellulose 1:2 Less yield 
Carbopol 1:2 Gel like product 
Sodium alginate 1:2 Gel like product  
Chitosan 1:2 No product 
Cyclodextrin 1:2 No yield 
Pectin 1:2 No product 
 
 Total ten formulations (F1-F5 and F6-F10) of Silymarin nanosponges with two 
different polymers ethyl cellulose and eudragit in different ratios were formulated 
by emulsion solvent diffusion method as given in Table 16 and Table 17. 
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Table 16: Formulation of Silymarin nanosponges 
S. No 
Formulation 
code 
Drug Polymer 
Drug : 
polymer 
ratio 
1 F1 
SILYMARIN 
Ethyl cellulose 1:0.5 
2 F2 Ethyl cellulose 1:1 
3 F3 Ethyl cellulose 1:1.5 
4 F4 Ethyl cellulose 1:2 
5 F5 Ethyl cellulose 1:3 
6 F6 Eudragit 1:0.5 
7 F7 Eudragit 1:1 
8 F8 Eudragit 1:1.5 
9 F9 Eudragit 1:2 
10 F10 Eudragit 1:2.5 
 
 
Table 17: Formulation of Silymarin nanosponges by emulsion solvent 
diffusion technique 
S. No Formulation 
code 
Weight of 
drug (mg) 
Weight of 
polymer (mg) 
Weight of poly 
vinyl alcohol 
(mg) 
1 F1 100 50 200 
2 F2 100 100 200 
3 F3 100 150 200 
4 F4 100 200 200 
5 F5 100 300 200 
6 F6 100 50 200 
7 F7 100 100 200 
8 F8 100 150 200 
9 F9 100 200 200 
10 F10 100 250 200 
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III. CHARACTERISATION OF SILYMARIN NANOSPONGES 
 
FTIR Spectroscopy of Silymarin Nanosponges 
FTIR spectrum of Silymarin nanosponges using ethyl cellulose is given in 
Figure12. 
 
Figure 12: FTIR spectrum of Silymarin nanosponges using EC 
 
Table 18: FTIR interpretation of Silymarin nanosponges using EC 
Materials Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional group 
assignment 
FORMULATION 
F4 
3650-3200 3615.88 
3478.95 
OH stretching 
2970-2850 2876.31 C-H stretching 
1725-1665 1668.23 C=O stretching 
1161-1029 1114.65 In plane =C-H 
bending 
800-600 876.488 
643.144 
C-H rocking 
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FTIR spectrum of Silymarin nanosponge using eudragit is given in Figure 13. 
 
Figure 13: FTIR spectrum of Silymarin nanosponges using Eudragit 
 
      Table 19: FTIR interpretation of Silymarin nanosponges using Eudragit 
Materials Standard wave 
number (cm-1) 
Test wave 
number (cm-1) 
Functional group 
assignment 
 
FORMULATION 
F9 
3650-3200 
3497.27 
3444.24 
OH stretching 
3300-2700 
2993.94 
2951.52 
C-H stretching 
1820-1665 1714.41 C=O stretching 
1800-1500 1638.23 N-H bending 
1500-1300 1449.24 C-H bending 
1320-1210 1271.82 C-O-C stretching 
1161-1029 1159.01 
In plane =C-H 
bending 
800-600 
753.066 
648.929 
C-H rocking 
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The peaks present in the FTIR spectra of pure Silymarin are present in the FTIR 
spectra of formulations F3 and F9. The FTIR interpretations indicated that the 
Silymarin is compatible with the excipients ethyl cellulose, eudragit and poly 
vinyl alcohol and no interactions observed in all formulations of nanosponges. 
 
Percentage yield analysis 
Percentage yield of the formulated Silymarin nanosponges were calculated using 
the formula: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑌𝑒𝑖𝑙𝑑 =  
𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑎𝑙 𝑦𝑖𝑒𝑙𝑑
𝑇ℎ𝑒𝑜𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑦𝑖𝑒𝑙𝑑 
 × 100 
 
Table 20: Percentage yield of Silymarin nanosponges 
 
 
The percentage yield was minimum for formulation F6 (32%) and maximum for 
formulation F5 (80.34%). From the results we can conclude that as the 
concentration of polymer increases the percentage yield also increases. It can also 
be noted that the yield obtained while using ethyl cellulose as polymer is much 
higher when compared with eudragit. The percentage yield of all formulations is 
depicted in Figure 14. 
S. No Formulation code Percentage yield (%) 
1. F1 65.76 
2. F2 71.25 
3. F3 73.28 
4. F4 78.16 
5. F5 80.34 
6. F6 32.08 
7. F7 34.14 
8. F8 48.57 
9. F9 49.75 
10. F10 57.22 
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Figure 14: Percentage yield analysis of Silymarin nanosponges 
 
Scanning Electron Microscopy 
SEM analyses of the formulated Silymarin nanosponges were performed to 
evaluate the surface morphology of nanosponges. The SEM images of 
formulations F4 and F9 are shown in Figure 15 and Figure 16 respectively. 
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Figure 15: SEM images of Silymarin nanosponges using Ethyl Cellulose 
 
 
SEM images showed the nanosponge was porous with a smooth surface 
morphology and spherical in shape. Due to evaporation of solvent, the 
nanosponge shell found to be smooth porous where outer surface was shiny 
smooth and inner surface was porous. The spongy and porous nature of the 
nanosponges can be seen in the above figures. The presence of pores was due to 
the impression of diffusion of the solvent dichloromethane. These results are in 
agreement with results obtained by Priyanka et al. (2018) [30].  
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Figure 16: SEM images of Silymarin nanosponges using eudragit 
 
Particle Size Measurement 
The particle size is one of the most important parameter for the characterisation of 
nanosponges. The average particle sizes of the prepared Silymarin nanosponges 
were measured using Malvern zeta sizer. 
Particle size analysis showed that the average particle size of Silymarin 
nanosponges formulated using ethyl cellulose (F4) was found to be 4097 nm with 
polydispersity index (PDI) value 1.000 and with intercept 1.41. The zeta size 
distribution of ethyl cellulose - silymarin nanosponges is depicted in Figure 17. 
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Figure 17: Zeta size distribution of Silymarin nanosponges (F4) 
 
Particle size analysis showed that the average particle size of Silymarin 
nanosponges formulated using eudragit was found to be 3811nm with PDI value 
1.000 and with intercept 1.33. The zeta size distribution of eudragit - Silymarin 
nanosponges is depicted in Figure 18. 
 
 
Figure 18: Zeta size distribution of Silymarin nanosponges (F9) 
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The particle size of nanosponges must be less than 5µm [1] (Ahmed R Z. et al.). 
The average particle size analyses of ethyl cellulose-Silymarin and eudragit-
Silymarin nanosponges are 4097nm and 3811nm respectively which are lesser 
than 5µm. 
Determination of Zeta Potential 
Zeta Potential was determined using Malvern zeta-sizer instrument. Zeta potential 
analysis is carried out to find the surface charge of the particles to know its 
stability during storage. The magnitude of zeta potential is predictive of the 
colloidal stability. Nanoparticles with zeta potential value greater than +25 mV or 
less than -25 mV typically have high degrees of stability. If all the particles in 
suspension have a large negative or positive zeta potential then they will tend to 
repel each other and there will be no tendency for the particles to come together. 
However, if the particles have low zeta potential values then there will be no force 
to prevent the particles coming together and flocculating. 
For Silymarin nanosponges using ethyl cellulose zeta potential was found to be 
 -15.2 mV with peak area of 100% intensity. These values indicate that the 
formulated Silymarin nanosponges (F4) are stable. Zeta potential distribution of 
Silymarin nanosponges prepared using ethyl cellulose is depicted in the Figure 19.   
 
 
Figure 19: Zeta potential of Silymarin nanosponges (F4) 
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For silymarin nanosponges using eudragit zeta potential was found to be    
-23.4mV with peak area of 100% intensity. These values indicate that the 
formulated Silymarin nanosponges (F9) are stable. Zeta potential distribution of 
Silymarin nanosponges prepared using eudragit is depicted in Figure 20. 
 
Figure 20: Zeta potential of Silymarin nanosponges (F9) 
Entrapment efficiency: 
 The amount of entrapped drug was calculated from the equation: 
% 𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑝𝑚𝑒𝑛𝑡 =  
𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡
 × 100 
Entrapment efficiency of prepared formulation is given in Table 21 and Figure 21. 
Figure 21: Entrapment efficiencies of Silymarin nanosponges 
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Table 21: Entrapment efficiencies of Silymarin nanosponges 
S. No Formulation code Entrapment Efficiency (%) 
1. F1 97.45 
2. F2 96.43  
3. F3 91.89 
4. F4 93.20 
5. F5 91.72 
6. F6 97.32 
7. F7 98.61 
8. F8 93.19 
9. F9 90.35 
10. F10 88.41 
 
The entrapment efficiency was found to be highest for F7 formulation (Silymarin: 
eudragit, ratio 1:1) which is 98.61% and the lowest entrapment of drug was found 
for F10 formulation (Silymarin: eudragit ratio 1:3). This might be due to the fact 
that the variation in entrapment efficiency was due to the changes in the polymer 
concentration and difference in the degree of cross linking (Viswanad et al.2015) 
[43]. The prepared nanosponges possess high drug entrapment efficiency and 
were found to be in the range of 88.41% - 98.61%. 
 
IN VITRO DRUG RELEASE STUDIES 
In vitro drug release study of the prepared Silymarin nanosponges was carried out 
using dialysis bag diffusion method. Amount of drug released in different time 
intervals were observed. 
In vitro drug release profile data obtained of Silymarin nanosponges containing 
ethyl cellulose (F1-F5) are given in Table 22 and Figure 22. 
 
 
Result and Discussion 
 
Department of Pharmaceutics  71 
 
Table 22: In vitro drug release profile of Silymarin nanosponges (F1-F5) 
Sl. No 
Time 
(hrs) 
Cumulative percentage drug release (%) 
F1 F2 F3 F4 F5 
1 0 0 0 0 0 0 
2 1 10.90 11.93 11.08 7.36 7.23 
3 2 18.62 20.26 15.7 9.33 8.96 
4 3 21.76 24.89 19.39 10.13 9.89 
5 4 26.00 30.01 21.24 13.11 11.54 
6 5 30.23 37.37 25.86 16.93 14.89 
7 6 37.94 42.73 27.71 22.19 18.16 
8 7 43.47 47.03 32.33 26.35 23.54 
9 8 45.18 50.96 35.68 29.71 28.18 
10 10 50.04 52.74 42.46 33.53 30.13 
11 12 52.14 55.16 46.89 40.05 38.91 
12 24 63.17 64.73 56.86 53.83 49.75 
13 32 69.90 69.16 64.90 58.12 53.67 
14 36 77.18 75.44 69.17 61.92 59.11 
15 48 89.90 88.79 81.75 72.86 67.56 
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Figure 22: In vitro drug release profile of Silymarin nanosponges (F1-F5) 
 
In vitro drug release profile data of Silymarin nanosponges containing eudragit 
(F6-F10) are given in Table 23 and Figure 23. 
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Table 23: In vitro drug release profile of Silymarin nanosponges (F6-F10) 
 
Sl. No 
Time  
(hrs) 
Cumulative percentage drug release (%) 
F6 F7 F8 F8 F10 
1 0 0 0 0 0 0 
2 1 13.44 14.32 14.06 8.99 7.45 
3 2 16.48 18.35 17.77 10.27 9.06 
4 3 22.39 22.14 22.26 11.30 10.87 
5 4 27.18 27.04 24.41 13.10 12.12 
6 5 31.4 30.05 29.05 13.87 15.68 
7 6 36.16 34.24 32.02 16.44 18.86 
8 7 41.64 41.08 36.57 20.55 24.98 
9 8 45.19 43.61 39.09 23.76 29.12 
10 10 51.4 49.35 43.43 36.99 32.19 
11 12 54.16 53.67 48.13 40.18 39.16 
12 24 62.41 62.53 55.89 48.91 50.80 
13 32 70.85 68.51 61.24 55.16 54.89 
14 36 76.18 73.27 66.75 61.19 60.23 
15 48 90.18 87.10 77.94 70.14 69.86 
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Figure 23: In vitro drug release profile of Silymarin nanosponges (F6-F10) 
 
From the in vitro release data it was found that formulations F1 and F2 showed 
the best release of 89.90% and 88.79% respectively at the end of 48 hrs among all 
the five formulations of Silymarin - ethyl cellulose nanosponges. Similarly F6 and 
F7 exhibited the best release of 90.19% and 87.10% respectively at the end of 48 
hrs among all the five formulations of Silymarin-eudragit nanosponges. The 
release rate was related to drug: polymer ratio. Increase of drug release was 
observed as a function of drug: polymer ratio. It was observed that the drug 
release decreased with an increase in the amount of polymer for each formulation. 
This may be due to the fact that the release of drug from the polymer matrix takes 
place after complete swelling of the polymer and as the amount of polymer in the 
formulation increases the time required to swell also increases. These results are 
in agreement with the release pattern of Silymarin nanoparticles observed by Hui-
ping-sun et al. (2016) [25]. 
The newly developed nanosponges exhibit a core shell structure with a 
hydrophobic core formed by either ethyl cellulose(F1-F5) and eudragit(F6-F10) 
and a hydrophilic shell formed by PVA macromolecules. The release showed a bi-
phasic pattern with an initial burst effect may be due to the unentrapped drug 
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adsorbed on the surface of the nanosponges. Drug release curve shows a faster 
release around 20%  in the first few hours which can be attributed to release of 
drug molecule adsorbed on the surface of nanosponges, while remaining drug 
released for further few hours say around 7-8 hours may stem from drug molecule 
physically entrapped within hydrophilic outer shell. At the same time, hydrophilic 
PVA molecules that form the shell could also solubilise within aqueous medium 
and release part of drug. Remaining drug is probably entrapped within the core of 
nanosponges and are released in the later time period. 
 
OPTIMIZATION OF SILYMARIN NANOSPONGES BY GENERAL FULL 
FACTORIAL DESIGN 
The factorial design is a technique that allows identification of factors involved in 
a process and assesses their relative importance. Full factorial design is one of the 
best tools to declare the effect of different variables on the parameters of any 
formulation. In addition, any interaction between factors chosen can be identified. 
Construction of a factorial design involves the selection of parameters and the 
choice of response. Factorial design was the first degree model because they have 
maximum efficiency in estimating main effects.  General full factorial design was 
created and analysed using Minitab software (Minitab 18 statistical software).  
Independent variables polymer type (A) at two levels (eudragit and ethyl 
cellulose) and drug: polymer ratio (B) at five levels (1:0.5, 1:1, 1:1.5, 1:2 and 
1:2.5) were used to find their influence on the dependent variable percentage drug 
released at the end of 48 hrs. The optimization of Silymarin nanosponges by 
general full factorial design is shown in Table 24 and Table 25. 
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Table 24: Factors for optimization by general full factorial design 
Factors 
Levels 
1 2 3 4 5 
Independent 
factors 
Polymer type 
(A) 
Ethyl 
cellulose 
Eudragit - - - 
Polymer 
concentration 
(B) 
1:0.5 1:1 1:1.5 1:2 1:2.5 
Dependent 
factors 
% drug released at the end of 48 hrs. 
 
 
 
Table 25: Optimization of Silymarin nanosponges by full factorial design 
Polymer type 
(A) 
Drug : Polymer Ratio 
(B) 
Percentage drug 
released at 48th hr 
(%) 
Ethyl cellulose(A1) 1:0.5(B1) 89.90 
Ethyl cellulose(A1) 1:1(B2) 88.79 
Ethyl cellulose(A1) 1:1.5(B3) 81.75 
Ethyl cellulose(A1) 1:2(B4) 72.86 
Ethyl cellulose(A1) 1:2.5(B5) 67.56 
Eudragit(A2) 1:0.5(B1) 90.18 
Eudragit(A2) 1:1(B2) 87.10 
Eudragit(A2) 1:1.5(B3) 77.94 
Eudragit(A2) 1:2(B4) 70.14 
Eudragit(A2) 1:2.5(B5) 69.86 
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Figure 24:  Main effects plot for drug release of Silymarin nanosponges 
 
Effect of Polymer Type  
Main effect plot of general full factorial design in Figure 24 reflected that the 
selected polymers has no much effect on the drug release pattern of Silymarin 
nanosponges. It may be due to the fact that both the polymers used (ethyl cellulose 
and eudragit) are hydrophobic in nature. The reason behind not selecting 
hydrophilic polymers in the formulation of nanosponges by emulsion solvent 
diffusion method was that they didn’t produce promising results in trial batches. 
So selected hydrophobic polymers (EC and eudragit) used in the formulation of 
Silymarin nanosponges have no significant effect on the drug release pattern. 
Effect of Drug: Polymer Ratio 
Main effects plot of general full factorial design in Figure 24 reflected that the 
drug: polymer ratio influences the drug release pattern of Silymarin nanosponges. 
For both the selected polymers (EC and eudragit), as the drug: polymer increases 
the drug release decreases significantly. It is assumed that the possible mechanism 
behind the drug release is a combination of dissolution, diffusion and erosion. The 
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decrease in release pattern may be due to the difficulty of the drug to diffuse 
through the hydrophobic core. 
 
IN-VITRO DRUG RELEASE KINETICS 
The data obtained from the in vitro release study was used to fit into kinetic models. 
This was done to find out the mechanism of drug release from Silymarin 
nanosponges. In order to determine the release model, the in vitro release data 
were analysed according to zero order, first order and diffusion controlled 
mechanism according to simplified Higuchi model. The preference of a certain 
mechanism was based on the coefficient of determination (r2) for the parameters 
studied, where the highest coefficient of determination is preferred for the 
selection of the order of release. The kinetic parameters of Silymarin nanosponges 
are shown in Table 26. 
 Since the r2 value is higher for Higuchi model, it is selected as the best fitted 
model. This was confirmed by plotting percentage cumulative drug release and 
square root of time and r2 value ranges between 0.8477 and 0.9888. This results 
are in agreement with results obtained by Srinivas et al.(2015) [45]. However, in 
many experimental situations, the mechanism of drug diffusion deviates from the 
Fickian equation and follows a non-Fickian (anomalous) behaviour. In these 
cases, the Korsemeyer–Peppas model was used to analyse the release kinetics. It is 
observed that formulation F1, F2, F6, F7 and F8 followed Fick’s law of diffusion 
and rest showed an anomalous behaviour. 
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Table 26: Kinetic parameters of the release data of Silymarin nanosponges 
 
Formula 
r2 
Mechanism 
Korsemeyer-Peppas Model 
Zero 
order 
First 
order 
Higuchi r2 n Mechanism 
F1 0.4432 0.8976 0.9664 Diffusion 0.9768 0.441 Fickian 
F2 0.1883 0.8307 0.9163 Diffusion 0.9637 0.386 Fickian 
F3 0.5983 0.9069 0.9888 Diffusion 0.9892 0.487 Anomalous 
F4 0.7729 0.9495 0.9674 Diffusion 0.9787 0.576 Anomalous 
F5 0.7831 0.9401 0.9602 Diffusion 0.9742 0.585 Anomalous 
F6 0.4323 0.8957 0.9652 Diffusion 0.9751 0.438 Fickian 
F7 0.3948 0.8719 0.9638 Diffusion 0.9798 0.429 Fickian 
F8 0.3404 0.7863 0.9620 Diffusion 0.9860 0.415 Fickian 
F9 0.7910 0.9388 0.9489 Diffusion 0.9657 0.595 Anomalous 
F10 0.7760 0.9412 0.9643 Diffusion 0.9765 0.579 Anomalous 
 
 
Drug release kinetic models of formulations F1, F2, F3, F4, F5, F6, F7, F8, F9 and 
F10 are shown in figures 25,26,27,28,29,30,31,32,33 and 34 respectively. 
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Figure 25: Drug release data of formulation F1 fitting to various kinetic 
models 
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Figure 26: Drug release data of formulation F2 fitting to various kinetic 
models 
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Figure 27: Drug release data of formulation F3 fitting to various kinetic 
models 
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Figure 28: Drug release data of formulation F4 fitting to various kinetic 
models 
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Figure 29: Drug release data of formulation F5 fitting to various kinetic 
models 
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Figure 30: Drug release data of formulation F6 fitting to various kinetic 
models 
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Figure31: Drug release data of formulation F7 fitting to various kinetic 
models 
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Figure 32: Drug release data of formulation F8 fitting to various kinetic 
models 
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Figure 33: Drug release data of formulation F9 fitting to various kinetic 
models 
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Figure 34: Drug release data of formulation F10 fitting to various kinetic 
models 
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SUMMARY AND CONCLUSION 
 
Nanosponges are microscopic particles with few nanometers wide cavities, 
in which a large variety of substances can be encapsulated. These particles possess 
the ability to carry both lipophilic and hydrophilic substances and thereby 
improving the solubility of poorly water soluble molecules. Drugs encapsulated 
within the nanosponge pores are shielded from premature destruction and stability 
of drug is enhanced. 
Silymarin, a potential phytochemical compound obtained from the seeds of 
Silybum marianum (milk thistle) plant has been used as a hepatoprotective agent, 
and shows strong anti-oxidant effect. Silymarin has been extensively studied in 
vitro and in vivo for its cancer chemopreventive potential against various cancers. 
The high incidence of administration of silymarin together with its short half-life 
and poor bioavailability proposed great scope for the proposal of nanoparticulate 
drug delivery systems. Various nanoformulation platforms employed as delivery 
vehicles for silibinin possess a major drawback in their low silibinin payloads.  
Main objective of this study was to formulate Silymarin loaded 
nanosponges using different polymers to target cancer cells (breast cancer, 
colorectal cancer or oesophageal cancer) and release the drug in a controlled 
manner. This formulation reduced the side effects, minimized the dosing 
frequency and dose. 
The present work aimed at formulating Silymarin nanosponges with two 
different types of polymers namely hydrophilic and hydrophobic polymers using 
emulsion solvent diffusion method. This method was simple and cost effective.  
Preformulation studies were carried out to find out the solubility of 
Silymarin. Solubility test gave an idea that silymarin is not water soluble but 
soluble in solvents like acetone, dichloromethane etc. 
FTIR and UV spectral studies authenticate the spectra obtained with the 
sample drug matched with standard pure drug. UV spectra gave the maximum 
absorption peak at 288nm.   
The comparison of FTIR spectra of Silymarin and mixture of Silymarin 
and polymer confirms that there is no appearance of additional new peaks and 
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disappearance of existing peaks from that of the drug. This indicates that there is 
no interaction between the drug and polymer used in the study. 
Formulation was carried out by emulsion solvent diffusion method. Trial 
batches indicated that hydrophilic polymers are not suitable for the Silymarin 
nanosponges. The hydrophilic polymers produced no yield or very less yield. 
Hydrophobic polymers produced good formulations. Ethyl cellulose and eudragit 
were selected for further studies. 
Scanning electron micrograph of the prepared nanosponges at different 
magnification showed that the nanosponges were porous with a smooth surface 
morphology and spherical shape. The spongy and porous nature of nanosponges 
was clearly observed in the SEM images. 
Particle size and zeta potential was determined by Malvern Zeta sizer. The 
particle size analysis confirmed that the prepared sample were in the nanometer 
range. Average particle size obtained for the formulations F4 and F9 were 
4097nm and 3811nm. Zeta potential values of nanosponges indicated that the 
formulated nanosponges are stable.   
The amount of drug being entrapped in nanosponges was calculated and 
all the prepared nanosponges were found to possess very high entrapment 
efficiency.  
From the in-vitro release data from the dialysis bag diffusion method it 
was found that formulations F1, F2, F6 and F7 showed the best release of 89.90%, 
88.79%, 90.19% and 87.10% respectively at the end of 48 hours. Increase of drug 
release was observed as a function of drug: polymer ratio. It was observed that the 
drug release decreased with an increase in the amount of polymer for each 
formulation. This is because the newly developed nanosponges is believed to 
exhibit a core shell structure with a hydrophobic core formed by ethyl 
cellulose(F1-F5) and eudragit(F6-F10) and a hydrophilic shell formed by PVA 
macromolecules. 
The formulations were optimized by general full factorial design using 
Minitab 18 statistical software. Effect of polymer type and drug: polymer ratio on 
the drug release pattern of formulated Silymarin nanosponges on drug release was 
studied. It was found that the polymer type has no significant effect on the drug 
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release pattern whereas the drug: polymer ratio has a significant effect on the 
release pattern of the drug. As the drug: polymer ratio increases the release of 
drug from the nanosponges decreases. Even though the drug release from both 
Silymarin- ethyl cellulose nanosponges (F5) and Silymarin- eudragit nanosponges 
(F10) are similar, the F5 formulation is selected as the optimum formulation due 
to its comparatively higher yield. 
The data obtained from the in vitro release study was fitted to the models 
which were used to find out the mechanism of drug release from silymarin 
nanosponges. The in vitro release model best fitted to Higuchi release order. This 
was confirmed by plotting percentage cumulative drug release and square root of 
time and r2 value ranges between 0.8477 and 0.9888. It is observed that 
formulation F1, F2, F6, F7 and F8 followed Fick’s law of diffusion and rest 
showed an anomalous behaviour. 
The Silymarin nanosponges can be formulated by cost effective and easy 
emulsion solvent diffusion method using hydrophobic polymers such as ethyl 
cellulose and eudragit. The formulated silymarin nanosponges can be used in the 
treatment of cancer such as prostate or colorectal cancer. This can be targeted to 
the cancer cells and produce sustained drug delivery which in turn reduces the 
dose, frequency of administration and the side effects. 
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